<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003456.pub3" GROUP_ID="NEUROMUSC" ID="254001052512181290" MERGED_FROM="" MODIFIED="2017-06-13 12:27:15 +0100" MODIFIED_BY="Ruth Brassington" REVIEW_NO="043" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2017-06-13 12:27:11 +0100" MODIFIED_BY="Ruth Brassington">
<TITLE>Drug therapy for chronic idiopathic axonal polyneuropathy</TITLE>
<CONTACT MODIFIED="2017-06-13 12:27:11 +0100" MODIFIED_BY="Ruth Brassington"><PERSON ID="15458" ROLE="AUTHOR"><FIRST_NAME>Alexander</FIRST_NAME><MIDDLE_INITIALS>FJE</MIDDLE_INITIALS><LAST_NAME>Vrancken</LAST_NAME><POSITION>MD PhD</POSITION><EMAIL_1>a.f.j.e.vrancken@umcutrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>University Medical Center Utrecht, Brain Center Rudolf Magnus</ORGANISATION><CITY>Utrecht</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 88 7551546</PHONE_1><PHONE_2>+31 88 7551882</PHONE_2><FAX_1>+31 88 7555494</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2017-06-13 12:27:11 +0100" MODIFIED_BY="Ruth Brassington"><PERSON ID="75463163667617569269100917133524" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Janna</FIRST_NAME><LAST_NAME>Warendorf</LAST_NAME><POSITION>Physician</POSITION><EMAIL_1>J.K.Warendorf@umcutrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Brain Center Rudolf Magnus, University Medical Center Utrecht</ORGANISATION><ADDRESS_1>Heidelberglaan 100</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3584 CX</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 5669111</PHONE_1><FAX_1>+31 20 6963489</FAX_1></ADDRESS></PERSON><PERSON ID="15458" ROLE="AUTHOR"><FIRST_NAME>Alexander</FIRST_NAME><MIDDLE_INITIALS>FJE</MIDDLE_INITIALS><LAST_NAME>Vrancken</LAST_NAME><POSITION>MD PhD</POSITION><EMAIL_1>a.f.j.e.vrancken@umcutrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>University Medical Center Utrecht, Brain Center Rudolf Magnus</ORGANISATION><CITY>Utrecht</CITY><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 88 7551546</PHONE_1><PHONE_2>+31 88 7551882</PHONE_2><FAX_1>+31 88 7555494</FAX_1></ADDRESS></PERSON><PERSON ID="5652" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ivo</FIRST_NAME><MIDDLE_INITIALS>N</MIDDLE_INITIALS><LAST_NAME>van Schaik</LAST_NAME><SUFFIX>MD PhD</SUFFIX><EMAIL_1>i.n.vanschaik@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Academic Medical Centre, University of Amsterdam</ORGANISATION><ADDRESS_1>Meibergdreef 9</ADDRESS_1><ADDRESS_2>PO Box 22700</ADDRESS_2><CITY>Amsterdam</CITY><ZIP>1100 DE</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>00 31 20 5669111 ext: 63842</PHONE_1><PHONE_2>+ 31 20 566 4012</PHONE_2><FAX_1>00 31 20 6971438</FAX_1></ADDRESS></PERSON><PERSON ID="7655" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Richard</FIRST_NAME><MIDDLE_INITIALS>AC</MIDDLE_INITIALS><LAST_NAME>Hughes</LAST_NAME><SUFFIX>MD FRCP FMedSci</SUFFIX><POSITION>Professor of Neurology</POSITION><EMAIL_1>rhughes11@btinternet.com</EMAIL_1><EMAIL_2>richard.hughes@ucl.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>MRC Centre for Neuromuscular Diseases</DEPARTMENT><ORGANISATION>National Hospital for Neurology and Neurosurgery</ORGANISATION><ADDRESS_1>PO Box 114</ADDRESS_1><ADDRESS_2>Queen Square</ADDRESS_2><CITY>London</CITY><ZIP>WC1N 3BG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7676 2060</PHONE_1><FAX_1>+44 20 7829 8725</FAX_1></ADDRESS></PERSON><PERSON ID="15421" ROLE="AUTHOR"><FIRST_NAME>Nicolette</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Notermans</LAST_NAME><POSITION>MD PhD</POSITION><EMAIL_1>n.c.notermans@umcutrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Brain Center Rudolf Magnus, University Medical Center Utrecht</ORGANISATION><ADDRESS_1>Heidelberglaan 100</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3584 CX</ZIP><REGION>Utrecht</REGION><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 30 2509111</PHONE_1><FAX_1>+31 30 2542100</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2017-01-20 13:39:12 +0000" MODIFIED_BY="Ruth Brassington">
<UP_TO_DATE>
<DATE DAY="7" MONTH="7" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="7" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="7" MONTH="7" YEAR="2020"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="6" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2017-05-12 12:26:28 +0100" MODIFIED_BY="Ruth Brassington">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-05-12 12:26:22 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="7" MONTH="7" YEAR="2016"/>
<DESCRIPTION>
<P>Minor edits. Conclusions unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-05-12 12:26:28 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="11" MONTH="4" YEAR="2016"/>
<DESCRIPTION>
<P>Searches incorporated. No new trials; 2 ongoing trials. Discussion updated with new non-randomised studies.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-04-11 22:16:30 +0100" MODIFIED_BY="Ruth Brassington">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-04-11 22:16:30 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="4" MONTH="3" YEAR="2013"/>
<DESCRIPTION>
<P>Added <LINK TAG="PUBLIC_NOTES" TYPE="SECTION">Published notes</LINK> concerning the next scheduled update of this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-03-04 15:10:08 +0000" MODIFIED_BY="Ruth Brassington">
<DATE DAY="15" MONTH="2" YEAR="2011"/>
<DESCRIPTION>
<P>Searches updated: the Cochrane Neuromuscular Disease Group Trials Register (April 2011), CENTRAL to Issue 1, 2011, MEDLINE (January 1981 to February 2011), EMBASE (January 1981 to February 2011), ISI (January 1981 to February 2011). No relevant trials were found. Discussion edited and references updated. Risk of bias section in methods revised.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-06-18 14:44:07 +0100" MODIFIED_BY="Kate Jewitt">
<DATE DAY="1" MONTH="7" YEAR="2006"/>
<DESCRIPTION>
<P>We updated the searches of the NMD Group Trials Register (April 2006), MEDLINE (January 1981 to May 2006), EMBASE (January 1981 to May 2006), ISI (January 1988 to May 2006) and ACP Journal Club's Best Evidence (January 1991 to May 2006). No randomised controlled trials were found. New non-randomised studies were added to the Discussion section of the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="10" MONTH="1" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2011-04-07 12:42:45 +0100" MODIFIED_BY="Ruth Brassington">
<INTERNAL_SOURCES MODIFIED="2011-04-07 12:42:45 +0100" MODIFIED_BY="Ruth Brassington">
<SOURCE MODIFIED="2011-04-07 12:42:45 +0100" MODIFIED_BY="Ruth Brassington">
<NAME>The Rudolf Magnus Institute for Neuroscience, University Medical Center Utrecht, Department of Neurology and Neuromuscular Diseases</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Academic Medical Center, University of Amsterdam, Department of Neurology</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>King's College London School of Medicine, London</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2011-04-07 12:42:15 +0100" MODIFIED_BY="Ruth Brassington">
<NAME>Cochrane Neuromuscular Disease Group, MRC Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, London</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Academic Medical Center, University of Amsterdam, Department of Biostatistics and Clinical Epidemiology</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-06-13 12:21:59 +0100" MODIFIED_BY="Ruth Brassington">
<SUMMARY MODIFIED="2017-06-13 12:18:00 +0100" MODIFIED_BY="Ruth Brassington">
<TITLE MODIFIED="2011-04-07 10:34:50 +0100" MODIFIED_BY="Ruth Brassington">Drug therapy for chronic idiopathic axonal polyneuropathy</TITLE>
<SUMMARY_BODY MODIFIED="2017-06-13 12:18:00 +0100" MODIFIED_BY="Ruth Brassington">
<P>
<B>What is the aim of this review?</B>
</P>
<P>The aim of this Cochrane Review was to assess the benefits and harms of drug therapy for chronic idiopathic axonal polyneuropathy (CIAP).</P>
<P>Cochrane Review authors collected and aimed to analyse all relevant studies to answer this question. This is the most recent update of a review first published in 2004.</P>
<P>
<B>Key messages</B>
</P>
<P>There have not been any randomised trials of drug therapy for CIAP. Future trials will need sensitive outcome measures and long follow-up periods.</P>
<P>
<B>What was studied in the review?</B>
</P>
<P>CIAP is a frequent disorder in elderly people that can reduce quality of life. Typically, the feet, lower legs and sometimes the hands slowly become numb or weak. The need for evidence-based treatments is increasing as the number of people affected is likely to rise in ageing populations. By definition, the cause of CIAP is unknown.</P>
<P>
<B>What are the main results of the review?</B>
</P>
<P>We found no trials suitable for review.</P>
<P>
<B>How up to date is this review?</B>
</P>
<P>The evidence is up to date to July 2016.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-06-13 12:17:43 +0100" MODIFIED_BY="Ruth Brassington">
<ABS_BACKGROUND MODIFIED="2017-05-12 12:26:51 +0100" MODIFIED_BY="Ruth Brassington">
<P>Chronic idiopathic axonal polyneuropathy (CIAP) is an insidiously progressive sensory or sensorimotor polyneuropathy that affects elderly people. Although severe disability or handicap does not occur, CIAP reduces quality of life. CIAP is diagnosed in 10% to 25% of people referred for evaluation of polyneuropathy. There is a need to gather and review emerging evidence on treatments, as the number of people affected is likely to increase in ageing populations. This is an update of a review first published in 2004 and previously updated in 2006, 2008, 2011 and 2013.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2017-06-13 12:17:21 +0100" MODIFIED_BY="Ruth Brassington">
<P>To assess the effects of drug therapy for chronic idiopathic axonal polyneuropathy for reducing disability and ameliorating neurological symptoms and associated impairments, and to assess any adverse effects of treatment.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-06-13 12:17:28 +0100" MODIFIED_BY="Ruth Brassington">
<P>In July 2016, we searched Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews in the Cochrane Library, MEDLINE, Embase, and the Web of Science. We searched two trials registries for ongoing trials. We also handsearched the reference lists of relevant articles, reviews and textbooks identified electronically, and we would have contacted authors and other experts in the field to identify additional studies if this seemed useful.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2017-06-13 12:17:39 +0100" MODIFIED_BY="Ruth Brassington">
<P>We sought all randomised or quasi-randomised (alternate or other systematic treatment allocation) trials that examined the effects of any drug therapy in people with CIAP at least one year after the onset of treatment. People with CIAP had to fulfil the following criteria: age 40 years or older, distal sensory or sensorimotor polyneuropathy, absence of systemic or other neurological disease, chronic clinical course not reaching a nadir in less than two months, exclusion of any recognised cause of the polyneuropathy by medical history taking, clinical or laboratory investigations, and electrophysiological studies in agreement with axonal polyneuropathy, without evidence of demyelinating features. The primary outcome was the proportion of participants with a significant improvement in disability. Secondary outcomes were change in the mean disability score, change in the proportion of participants who make use of walking aids, change in the mean Medical Research Council sum score, degree of pain relief and/or reduction of other positive sensory symptoms, change in the proportion of participants with pain or other positive sensory symptoms, and frequency of adverse effects.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2017-03-17 10:08:50 +0000" MODIFIED_BY="Ruth Brassington">
<P>Two review authors independently reviewed the results of the literature search and extracted details of trial methodology and outcome data of all potentially relevant trials.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2017-06-13 12:17:43 +0100" MODIFIED_BY="Ruth Brassington">
<P>We identified 39 studies and assessed them for possible inclusion in the review, but we excluded all of them because of insufficient quality or lack of relevance. We summarised evidence from non-randomised studies in the Discussion.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-04-11 22:34:06 +0100" MODIFIED_BY="Ruth Brassington">
<P>Even though CIAP has been clearly described and delineated, no adequate randomised or quasi-randomised controlled clinical treatment trials have been performed. In their absence there is no proven efficacious drug therapy.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-06-13 12:21:54 +0100" MODIFIED_BY="Ruth Brassington">
<BACKGROUND MODIFIED="2017-06-13 12:18:30 +0100" MODIFIED_BY="Ruth Brassington">
<P>Chronic idiopathic axonal polyneuropathy (CIAP) typically presents in the sixth decade and is characterised by an insidious onset of predominantly sensory or sensorimotor dysfunction in the legs (<LINK REF="REF-Grahmann-1991" TYPE="REFERENCE">Grahmann 1991</LINK>; <LINK REF="REF-McLeod-1984" TYPE="REFERENCE">McLeod 1984</LINK>; <LINK REF="REF-Notermans-1993" TYPE="REFERENCE">Notermans 1993</LINK>; <LINK REF="REF-Wolfe-1999" TYPE="REFERENCE">Wolfe 1999</LINK>). In about 45% of people who have the condition, the polyneuropathy evolves to affect the hands, but involvement of the proximal limbs or cranial nerves does not occur. The distal parts of the limbs are usually symmetrically affected. All those affected have sensory disturbances in the legs, and many also have distal leg weakness. Areflexia is uncommon and usually confined to the ankles or, less frequently, the knees. By definition, electrophysiological studies invariably show an axonal polyneuropathy (<LINK REF="REF-Lindh-2005" TYPE="REFERENCE">Lindh 2005</LINK>; <LINK REF="REF-McLeod-1984" TYPE="REFERENCE">McLeod 1984</LINK>; <LINK REF="REF-Notermans-1993" TYPE="REFERENCE">Notermans 1993</LINK>; <LINK REF="REF-Wolfe-1999" TYPE="REFERENCE">Wolfe 1999</LINK>). The clinical course of CIAP is slowly progressive and often reaches a plateau. Severe disability or handicap does not occur, but quality of life may be reduced (<LINK REF="REF-Grahmann-1991" TYPE="REFERENCE">Grahmann 1991</LINK>; <LINK REF="REF-Lindh-2005" TYPE="REFERENCE">Lindh 2005</LINK>; <LINK REF="REF-Lindh-2011a" TYPE="REFERENCE">Lindh 2011a</LINK>; <LINK REF="REF-McLeod-1984" TYPE="REFERENCE">McLeod 1984</LINK>; <LINK REF="REF-Notermans-1994" TYPE="REFERENCE">Notermans 1994</LINK>; <LINK REF="REF-Teunissen-2000a" TYPE="REFERENCE">Teunissen 2000a</LINK>; <LINK REF="REF-Vrancken-2002a" TYPE="REFERENCE">Vrancken 2002a</LINK>; <LINK REF="REF-Wolfe-1999" TYPE="REFERENCE">Wolfe 1999</LINK>).</P>
<P>A diagnosis of CIAP can be reached only after exclusion of other causes of axonal polyneuropathy by extensive clinical and laboratory investigations (<LINK REF="REF-Farhad-2015" TYPE="REFERENCE">Farhad 2015</LINK>; <LINK REF="REF-McLeod-1984" TYPE="REFERENCE">McLeod 1984</LINK>; <LINK REF="REF-Notermans-1993" TYPE="REFERENCE">Notermans 1993</LINK>; <LINK REF="REF-Rosenberg-2004" TYPE="REFERENCE">Rosenberg 2004</LINK>). CIAP has no characteristic histopathological features. The pathological findings mainly consist of axonal degeneration and regeneration, as well as an increase in endoneurial vessels with basal lamina thickening. Inflammatory changes (increased numbers of inflammatory cells or cellular infiltration) are absent (<LINK REF="REF-Chia-1996" TYPE="REFERENCE">Chia 1996</LINK>; <LINK REF="REF-Teunissen-2000c" TYPE="REFERENCE">Teunissen 2000c</LINK>; <LINK REF="REF-Vrancken-2004a" TYPE="REFERENCE">Vrancken 2004a</LINK>). At the ultrastructural level an increased thickness of endoneurial vessel basal lamina can be found, but this is a non-specific finding (<LINK REF="REF-Teunissen-2000c" TYPE="REFERENCE">Teunissen 2000c</LINK>). Consequently, sural nerve biopsy contributes only if another cause of the polyneuropathy is suspected on clinical or laboratory grounds, because histopathological confirmation of an underlying disorder can affect patient management (<LINK REF="REF-Chia-1996" TYPE="REFERENCE">Chia 1996</LINK>; <LINK REF="REF-Deprez-2000" TYPE="REFERENCE">Deprez 2000</LINK>; <LINK REF="REF-Gabriel-2000" TYPE="REFERENCE">Gabriel 2000</LINK>; <LINK REF="REF-Logigian-1994" TYPE="REFERENCE">Logigian 1994</LINK>).</P>
<P>It is uncertain whether CIAP should be seen as a single entity with a particular (and so far unknown) pathogenesis or whether it represents a heterogeneous group of conditions that share a similar clinical phenotype. Because CIAP typically presents in the elderly and is diagnosed in 10% to 25% of people referred for evaluation of polyneuropathy (<LINK REF="REF-Camerlingo-1998" TYPE="REFERENCE">Camerlingo 1998</LINK>; <LINK REF="REF-Dyck-1981" TYPE="REFERENCE">Dyck 1981</LINK>; <LINK REF="REF-Farhad-2015" TYPE="REFERENCE">Farhad 2015</LINK>; <LINK REF="REF-Grahmann-1991" TYPE="REFERENCE">Grahmann 1991</LINK>; <LINK REF="REF-McLeod-1984" TYPE="REFERENCE">McLeod 1984</LINK>; <LINK REF="REF-Notermans-1993" TYPE="REFERENCE">Notermans 1993</LINK>; <LINK REF="REF-Vilming-1987" TYPE="REFERENCE">Vilming 1987</LINK>; <LINK REF="REF-Visser-2015" TYPE="REFERENCE">Visser 2015</LINK>; <LINK REF="REF-Wolfe-1999" TYPE="REFERENCE">Wolfe 1999</LINK>), the number of people affected and disabled by this condition is expected to increase in the continuously ageing population (<LINK REF="REF-Verghese-2001" TYPE="REFERENCE">Verghese 2001</LINK>; <LINK REF="REF-Visser-2015" TYPE="REFERENCE">Visser 2015</LINK>). Hence, the need for therapy of CIAP is increasing. This is an update of a review first published in 2004.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2017-06-13 12:18:33 +0100" MODIFIED_BY="Ruth Brassington">
<P>To assess the effects of drug therapy for chronic idiopathic axonal polyneuropathy for reducing disability and ameliorating neurological symptoms and associated impairments, and to assess any adverse effects of treatment.</P>
</OBJECTIVES>
<METHODS MODIFIED="2017-06-13 12:20:27 +0100" MODIFIED_BY="Ruth Brassington">
<SELECTION_CRITERIA MODIFIED="2017-06-13 12:19:36 +0100" MODIFIED_BY="Ruth Brassington">
<CRIT_STUDIES MODIFIED="2017-06-13 12:18:48 +0100" MODIFIED_BY="Ruth Brassington">
<P>We intended to include all randomised or quasi-randomised (alternate or other systematic treatment allocation) studies examining the effects of drug therapy in participants with chronic idiopathic axonal polyneuropathy (CIAP) at least one year after the onset of treatment.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2017-06-13 12:19:13 +0100" MODIFIED_BY="Ruth Brassington">
<P>Eligible studies had to include adult participants aged 40 years or older who fulfilled the following criteria for CIAP (<LINK REF="REF-Notermans-1993" TYPE="REFERENCE">Notermans 1993</LINK>; <LINK REF="REF-Vrancken-2002a" TYPE="REFERENCE">Vrancken 2002a</LINK>).</P>
<OL>
<LI>Distal sensory or sensory and motor symptoms and signs of the limbs compatible with polyneuropathy.</LI>
<LI>Absence of systemic or neurological disease that could explain the symptoms or signs.</LI>
<LI>Chronic clinical course, not reaching a nadir in less than two months.</LI>
<LI>Exclusion of any recognised cause of the polyneuropathy, such as diabetes mellitus, renal insufficiency, biliary cirrhosis, alcohol abuse, medication use, toxic substance exposure, thyroid disorder, vitamin deficiency, malignancy, polycythaemia, monoclonal protein, systemic autoimmune disease, inflammatory bowel disease, metabolic storage disease, sarcoidosis and amyloidosis, by medical history taking and clinical or laboratory investigations.</LI>
<LI>No indication of hereditary polyneuropathy.</LI>
<LI>Electrophysiological studies in agreement with axonal polyneuropathy without demyelinating features.</LI>
</OL>
<P>Sural nerve biopsy was not mandatory but should have been performed whenever there was any suspicion on clinical or laboratory grounds of an inflammatory or infiltrating disorder (i.e. vasculitis, amyloidosis, or sarcoidosis) or inherited storage disorder (<LINK REF="REF-McLeod-1984" TYPE="REFERENCE">McLeod 1984</LINK>; <LINK REF="REF-Notermans-1993" TYPE="REFERENCE">Notermans 1993</LINK>; <LINK REF="REF-Vrancken-2004a" TYPE="REFERENCE">Vrancken 2004a</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2017-03-17 10:09:33 +0000" MODIFIED_BY="Ruth Brassington">
<P>We would have included any drug therapy versus no therapy, placebo or another drug therapy ('head-to-head' comparison study design). We placed no restrictions on the route of administration.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2017-06-13 12:19:36 +0100" MODIFIED_BY="Ruth Brassington">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2017-06-13 12:19:23 +0100" MODIFIED_BY="Ruth Brassington">
<P>The proportion of participants with a significant improvement in disability as determined by the original authors within or up to one year after the onset of treatment. Where possible, we would have transformed disability data to a modified Rankin scale (<LINK REF="REF-Rankin-1957" TYPE="REFERENCE">Rankin 1957</LINK>; <LINK REF="REF-van-Swieten-1988" TYPE="REFERENCE">van Swieten 1988</LINK>).</P>
<UL>
<LI>0 = healthy; no signs or symptoms.</LI>
<LI>1 = no significant disability despite signs and/or symptoms; able to carry out all usual duties.</LI>
<LI>2 = slight disability: unable to carry out usual duties but able to look after own affairs without assistance.</LI>
<LI>3 = moderate disability: requires some help but able to walk without assistance, remains self-supporting.</LI>
<LI>4 = moderately severe disability: unable to walk without assistance and unable to attend to own bodily needs without assistance; is only partly self-supporting.</LI>
<LI>5 = severe disability: bedridden and requiring constant care-taking and attention.</LI>
</UL>
<P>If necessary, we would have asked trial authors for original data to enable this transformation. We defined improvement as at least one point decrease on this modified Rankin scale; we considered unchanged or increased scoring on the modified Rankin scale as no improvement.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2017-06-13 12:19:36 +0100" MODIFIED_BY="Ruth Brassington">
<P>We considered the following secondary outcome measures (assessed within or up to one year after the onset of treatment and compared to baseline).</P>
<OL>
<LI>Change in the mean disability score as determined by the original authors, expressed as standardised mean difference (SMD). Where possible, we would have transformed disability data to the modified Rankin scale as described above.</LI>
<LI>Change in the proportion of participants that makes use of walking aids.</LI>
<LI>Change in the mean Medical Research Council (MRC) sum score (<LINK REF="REF-Kleyweg-1991" TYPE="REFERENCE">Kleyweg 1991</LINK>; <LINK REF="REF-Notermans-1994" TYPE="REFERENCE">Notermans 1994</LINK>; <LINK REF="REF-Vrancken-2002a" TYPE="REFERENCE">Vrancken 2002a</LINK>), expressed as SMD.</LI>
<LI>Degree of pain relief, reduction of other positive sensory symptoms or both, as determined by the original authors, expressed as SMD.</LI>
<LI>Change in the proportion of participants with pain or other positive sensory symptoms.</LI>
<LI>Frequency of adverse effects.</LI>
</OL>
<P>If necessary for the meta-analysis, we would have re-scaled the results using the primary or secondary outcome measures from studies with different follow-up periods on the assumption of constant rates of change.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-06-13 12:19:41 +0100" MODIFIED_BY="Ruth Brassington">
<ELECTRONIC_SEARCHES MODIFIED="2017-06-13 12:19:38 +0100" MODIFIED_BY="Ruth Brassington">
<P>The review authors performed all searches themselves.</P>
<P>We searched:</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL, Issue 6 2016) in the Cochrane Library (searched 8 July 2016);</LI>
<LI>Cochrane Database of Systematic Reviews (Issue 6, 2016) in the Cochrane Library (searched 8 July 2016);</LI>
<LI>MEDLINE (1981 to 8 July 2016);</LI>
<LI>Embase (1981 to 6 July 2016);</LI>
<LI>Web of Science (1981 to 7 July 2016);</LI>
<LI>ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>; searched 7 July 2016); and</LI>
<LI>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://apps.who.int/trialsearch">apps.who.int/trialsearch</A>; searched 7 July 2016).</LI>
</UL>
<P>We used the following keywords as MeSH terms and text words (and their combinations and truncated synonyms) to guide these searches: 'chronic polyneuropathy', 'axonal polyneuropathy', 'cryptogenic polyneuropathy', and 'idiopathic polyneuropathy'. The search began from 1981, when Dyck and colleagues first recognised the clinical entity of idiopathic axonal polyneuropathy (<LINK REF="REF-Dyck-1981" TYPE="REFERENCE">Dyck 1981</LINK>).</P>
<P>See the appendices for search strategies: Cochrane Register of Studies/Cochrane Central Register of Controlled Trials (CENTRAL; <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), the Cochrane Library (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), MEDLINE Ovid (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), Embase (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>), Web of Science (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>), ClinicalTrials.gov (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>) and WHO ICTRP <LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2017-06-13 12:19:41 +0100" MODIFIED_BY="Ruth Brassington">
<P>We handsearched the reference lists of relevant published studies, reviews, meta-analyses and textbooks to identify additional studies. We invite readers to suggest studies, particularly in other languages, that we should consider for inclusion when the review is next updated. We would have contacted authors and other experts in the field to identify additional studies if this seemed useful.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-06-13 12:20:27 +0100" MODIFIED_BY="Ruth Brassington">
<STUDY_SELECTION MODIFIED="2017-06-13 12:19:43 +0100" MODIFIED_BY="Ruth Brassington">
<P>Two authors (AV and IS or JW) independently reviewed the titles and abstracts from literature searches to identify potentially relevant trials for full review. From the full texts, we would have selected trials that met the selection criteria and graded their risk of bias. Review authors were not blinded to trial author or source institution. We would have resolved disagreement by consensus with third party adjudication if necessary.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2017-06-13 12:19:45 +0100" MODIFIED_BY="Ruth Brassington">
<P>Two review authors (AV and IS or JW) would have independently extracted data onto specially designed, pre-piloted collection forms. We would have obtained missing data from the trial authors whenever possible. We would have resolved disagreements by consultation with a third author until we reached consensus.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2017-06-13 12:19:47 +0100" MODIFIED_BY="Ruth Brassington">
<P>We would have assessed concealment of treatment allocation, randomisation, incomplete outcome data (and intention-to-treat analysis), selective outcome reporting, participant and personnel blinding, observer blinding, and other sources of bias. We would have scored each item according to the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> as conferring a low, high or unclear (uncertain) risk of bias (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Two authors (AV and IS or JW) would have graded the risk of bias independently. In case of disagreement, we would have consulted another review author for resolution by consensus.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2017-06-13 12:19:50 +0100" MODIFIED_BY="Ruth Brassington">
<P>We would have used Review Manager 5 (RevMan 5) software to carry out calculations (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We would have calculated risk ratios (RRs) from dichotomised proportional data for each study. We would have calculated the pooled risk ratio estimate to assess the overall efficacy of the intervention in comparable studies.</P>
<P>We would have calculated mean differences (MD) from the mean changes in disability scores and MRC scores for each study if studies used the same measure. If studies used different measurement tools for the same continuous outcome we would have calculated the standardised mean difference (SMD) to combine results. We planned to derive standard deviations for each study by calculation or extraction from the available data. If necessary we would have asked trial authors for the original data. For all analyses, we would have determined 95% confidence intervals.</P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2017-05-12 14:42:51 +0100" MODIFIED_BY="Ruth Brassington">
<P>We would have quantified heterogeneity of data by I<SUP>2 </SUP>analysis (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). If this analysis had shown heterogeneity to be low (I<SUP>2</SUP> smaller than or equal to 25%), we would have used the Mantel-Haenszel fixed-effect model. Otherwise, we would have carried out sensitivity analyses first to explore the plausible cause of the heterogeneity of data.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2017-06-13 12:20:03 +0100" MODIFIED_BY="Ruth Brassington">
<P>We planned to use a fixed-effect meta-analysis as noted above. If heterogeneity were not due to differences between identifiable and separable subgroups of studies, we would have employed the random-effects model of DerSimonian and Laird (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2017-06-13 12:20:09 +0100" MODIFIED_BY="Ruth Brassington">
<P>We would have performed subgroup analyses to explore possible differences in treatment efficacy between participants younger than 65 years and 65 years and older, and between participants with a nadir of neurological deficits within or after 12 months from the onset of symptoms and signs (<LINK REF="REF-Vrancken-2002a" TYPE="REFERENCE">Vrancken 2002a</LINK>; <LINK REF="REF-Vrancken-2004a" TYPE="REFERENCE">Vrancken 2004a</LINK>).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2017-06-13 12:20:27 +0100" MODIFIED_BY="Ruth Brassington">
<P>We would have performed a sensitivity analysis on the basis of risk of bias, according to the presence or absence of allocation concealment and other bias domains. We would have also used sensitivity analyses to explore the origin of unexplained heterogeneity within analyses.</P>
<SUBSECTION>
<HEADING LEVEL="3">'Summary of findings' table</HEADING>
<P>If RCTs are available for inclusion in future updates, we will create a 'Summary of findings' table using the outcomes listed under <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>
<I>. </I>We will use the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence (studies that contribute data for the prespecified outcomes). We will use methods and recommendations described in Section 8.5 and Chapter 12 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) using GRADEpro software. Two or more authors will grade the evidence independently and resolve differences by consensus. We will justify all decisions to downgrade or upgrade the quality of studies using footnotes, and we will make comments to aid readers' understanding of the review where necessary.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-06-13 12:21:06 +0100" MODIFIED_BY="Ruth Brassington">
<STUDY_DESCRIPTION MODIFIED="2017-06-13 12:21:06 +0100" MODIFIED_BY="Ruth Brassington">
<P>For this updated review the number of studies found by the new, current search strategies were: MEDLINE, 564 (197 new); Embase, 87 (49 new); Cochrane Reviews in the <I>Cochrane Library,</I> 143 (61 new); CENTRAL, 188 (117 new); and Web of Science, 158 (57 new). We identified and assessed 42 studies (12 new) for possible inclusion in the review. Twenty-two studies did not show separate data for participants with idiopathic (poly)neuropathy (<LINK REF="STD-Attal-2016" TYPE="STUDY">Attal 2016</LINK>; <LINK REF="STD-De-Grandis-1995" TYPE="STUDY">De Grandis 1995</LINK>; <LINK REF="STD-Demant-2014" TYPE="STUDY">Demant 2014</LINK>; <LINK REF="STD-Gilron-2011" TYPE="STUDY">Gilron 2011</LINK>; <LINK REF="STD-Hewitt-2011" TYPE="STUDY">Hewitt 2011</LINK>; <LINK REF="STD-Holbech-2011" TYPE="STUDY">Holbech 2011</LINK>; <LINK REF="STD-Husstedt-1993" TYPE="STUDY">Husstedt 1993</LINK>; <LINK REF="STD-Jensen-2012" TYPE="STUDY">Jensen 2012</LINK>; <LINK REF="STD-Kishore_x002d_Kumar-1989" TYPE="STUDY">Kishore-Kumar 1989</LINK>; <LINK REF="STD-Li-2010" TYPE="STUDY">Li 2010</LINK>; <LINK REF="STD-Low-1995" TYPE="STUDY">Low 1995</LINK>; <LINK REF="STD-Morley-2003" TYPE="STUDY">Morley 2003</LINK>; <LINK REF="STD-Otto-2008" TYPE="STUDY">Otto 2008</LINK>; <LINK REF="STD-Raber-2015" TYPE="STUDY">Raber 2015</LINK>; <LINK REF="STD-Sindrup-1999a" TYPE="STUDY">Sindrup 1999a</LINK>; <LINK REF="STD-Sindrup-1999b" TYPE="STUDY">Sindrup 1999b</LINK>; <LINK REF="STD-Sindrup-2001" TYPE="STUDY">Sindrup 2001</LINK>; <LINK REF="STD-Sindrup-2003" TYPE="STUDY">Sindrup 2003</LINK>; <LINK REF="STD-Sindrup-2012" TYPE="STUDY">Sindrup 2012</LINK>; <LINK REF="STD-Vrethem-1997" TYPE="STUDY">Vrethem 1997</LINK>; <LINK REF="STD-Wallace-2000" TYPE="STUDY">Wallace 2000</LINK>; <LINK REF="STD-Wilsey-2013" TYPE="STUDY">Wilsey 2013</LINK>); 17 studies included participants with neuropathic pain and painful (poly)neuropathy of various, unspecified or unclear origin (<LINK REF="STD-Frank-2008" TYPE="STUDY">Frank 2008</LINK>; <LINK REF="STD-Galer-2000" TYPE="STUDY">Galer 2000</LINK>; <LINK REF="STD-Haanpaa-2016" TYPE="STUDY">Haanpaa 2016</LINK>; <LINK REF="STD-Ho-2008" TYPE="STUDY">Ho 2008</LINK>; <LINK REF="STD-Huge-2010" TYPE="STUDY">Huge 2010</LINK>; <LINK REF="STD-Langohr-1982" TYPE="STUDY">Langohr 1982</LINK>; <LINK REF="STD-Maier-2002" TYPE="STUDY">Maier 2002</LINK>; <LINK REF="STD-Meier-2003" TYPE="STUDY">Meier 2003</LINK>; <LINK REF="STD-Nurmikko-2007" TYPE="STUDY">Nurmikko 2007</LINK>; <LINK REF="STD-Onofrj-1995" TYPE="STUDY">Onofrj 1995</LINK>; <LINK REF="STD-Otto-2004" TYPE="STUDY">Otto 2004</LINK>; <LINK REF="STD-Pedersen-2014" TYPE="STUDY">Pedersen 2014</LINK>; <LINK REF="STD-Rauck-2006" TYPE="STUDY">Rauck 2006</LINK>; <LINK REF="STD-Rowbotham-2003" TYPE="STUDY">Rowbotham 2003</LINK>; <LINK REF="STD-Semenchuk-2001" TYPE="STUDY">Semenchuk 2001</LINK>; <LINK REF="STD-Serpell-2014" TYPE="STUDY">Serpell 2014</LINK>; <LINK REF="STD-Wallace-2002" TYPE="STUDY">Wallace 2002</LINK>); 3 studies did not include useful outcome measures (<LINK REF="STD-Bradley-1988" TYPE="STUDY">Bradley 1988</LINK>; <LINK REF="STD-De-Grandis-1995" TYPE="STUDY">De Grandis 1995</LINK>; <LINK REF="STD-Husstedt-1993" TYPE="STUDY">Husstedt 1993</LINK>); and 2 studies concerned participants with painful idiopathic small fiber predominant neuropathy (<LINK REF="STD-Ho-2009" TYPE="STUDY">Ho 2009</LINK>; <LINK REF="STD-Windebank-2004" TYPE="STUDY">Windebank 2004</LINK>). In none of the assessed studies did the participants with idiopathic (poly)neuropathy fulfil our criteria for CIAP. Thus, we excluded all studies for this review update. We have provided details of all the excluded studies in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<P>At this update, we identified two potentially eligible ongoing studies: one randomised study of the safety and effectiveness of nortriptyline, duloxetine, pregabalin and mexiletine for treating cryptogenic sensory polyneuropathy (<LINK REF="STD-NCT02260388" TYPE="STUDY">NCT02260388</LINK>), and another randomised, double-blind, controlled study of lidocaine for neuropathic pain (<LINK REF="STD-NCT02597257" TYPE="STUDY">NCT02597257</LINK>). See <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-04-03 15:58:26 +0100" MODIFIED_BY="Ruth Brassington">
<P>No studies were of sufficient quality to be included.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2017-04-03 15:58:26 +0100" MODIFIED_BY="Ruth Brassington">
<P>No included studies.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-06-13 12:21:54 +0100" MODIFIED_BY="Ruth Brassington">
<P>Even though chronic idiopathic axonal polyneuropathy (CIAP) has been clearly described and delineated, no adequate randomised or quasi-randomised controlled clinical trials for its treatment have been published. Perhaps the mild and non-severely disabling clinical course has until now obviated the need for such studies, but since the neurological symptoms and signs interfere with physical functioning and activities of daily living, and consequently lead to a reduced quality of life, it is justifiable to seek treatments.</P>
<P>In the only open study that included five participants with a more progressive course of idiopathic axonal polyneuropathy (i.e. nadir within one year of disease onset, and no evidence of vasculitis or inflammation in a sural nerve biopsy), investigators observed no clear benefit for treatment with oral prednisone or intravenous immunoglobulin (<LINK REF="REF-Vrancken-2004a" TYPE="REFERENCE">Vrancken 2004a</LINK>). Thus, at present there are no promising observational studies to guide the choice of treatment for CIAP.</P>
<P>In the absence of a proper understanding of the pathogenesis of CIAP, it is not possible to propose specific treatments for study. Given that this is an axonal peripheral neuropathy, it may appear relatively unlikely that any current therapeutic approach could cause improvement with respect to the primary outcome measure, and that at best stabilisation or slowing in deterioration could be achieved in terms of the secondary outcome measures.</P>
<P>There may be an association between impaired glucose tolerance and idiopathic painful sensory neuropathy (<LINK REF="REF-Rajabally-2011a" TYPE="REFERENCE">Rajabally 2011a</LINK>), but for CIAP this is very uncertain (<LINK REF="REF-Nebuchennykh-2008" TYPE="REFERENCE">Nebuchennykh 2008</LINK>; <LINK REF="REF-Visser-2013" TYPE="REFERENCE">Visser 2013</LINK>). Moreover, in follow-up studies participants with CIAP did not develop diabetes (<LINK REF="REF-Jann-2001" TYPE="REFERENCE">Jann 2001</LINK>; <LINK REF="REF-Notermans-1994" TYPE="REFERENCE">Notermans 1994</LINK>; <LINK REF="REF-Vrancken-2002a" TYPE="REFERENCE">Vrancken 2002a</LINK>). Chronic obstructive pulmonary disease, subtle cobalamin deficiency, use of statins, vitamin B6 exposure, cardiovascular disease or associated risk factors such as hypertriglyceridaemia, hypertension, obesity, or the metabolic syndrome, and exposure to environmental or occupational risk factors have been implicated in predisposing to polyneuropathy without a cause, that is idiopathic or cryptogenic (axonal) polyneuropathy (<LINK REF="REF-Baldereschi-2013" TYPE="REFERENCE">Baldereschi 2013</LINK>; <LINK REF="REF-Bays-2006" TYPE="REFERENCE">Bays 2006</LINK>; <LINK REF="REF-Hughes-2004" TYPE="REFERENCE">Hughes 2004</LINK>; <LINK REF="REF-Jann-1998" TYPE="REFERENCE">Jann 1998</LINK>; <LINK REF="REF-Lindh-2011b" TYPE="REFERENCE">Lindh 2011b</LINK>; <LINK REF="REF-Persson-2013" TYPE="REFERENCE">Persson 2013</LINK>; <LINK REF="REF-Poza-1997" TYPE="REFERENCE">Poza 1997</LINK>; <LINK REF="REF-Rajabally-2011b" TYPE="REFERENCE">Rajabally 2011b</LINK>; <LINK REF="REF-Saperstein-2003" TYPE="REFERENCE">Saperstein 2003</LINK>; <LINK REF="REF-Singer-2012" TYPE="REFERENCE">Singer 2012</LINK>; <LINK REF="REF-Smith-2008" TYPE="REFERENCE">Smith 2008</LINK>; <LINK REF="REF-Teunissen-2002" TYPE="REFERENCE">Teunissen 2002</LINK>; <LINK REF="REF-Tierney-2013" TYPE="REFERENCE">Tierney 2013</LINK>; <LINK REF="REF-Tondel-2006" TYPE="REFERENCE">Tondel 2006</LINK>; <LINK REF="REF-Visser-2013" TYPE="REFERENCE">Visser 2013</LINK>; <LINK REF="REF-Visser-2014" TYPE="REFERENCE">Visser 2014</LINK>). The microvascular changes in nerve biopsies of people with CIAP further support the hypothesis that chronic ischaemia or hypoxaemia could play a role in the pathogenesis of CIAP (<LINK REF="REF-Teunissen-2000b" TYPE="REFERENCE">Teunissen 2000b</LINK>; <LINK REF="REF-Teunissen-2000c" TYPE="REFERENCE">Teunissen 2000c</LINK>). Thus, drug treatment or lifestyle changes similar to those recommended for (risk factors of) cardiovascular disease or diabetes are worth considering (<LINK REF="REF-Bhalla-2014" TYPE="REFERENCE">Bhalla 2014</LINK>; <LINK REF="REF-Cameron-2001" TYPE="REFERENCE">Cameron 2001</LINK>; <LINK REF="REF-Eliasson-2003" TYPE="REFERENCE">Eliasson 2003</LINK>; <LINK REF="REF-Forrest-1997" TYPE="REFERENCE">Forrest 1997</LINK>; <LINK REF="REF-Hernandez_x002d_Ojeda-2014" TYPE="REFERENCE">Hernandez-Ojeda 2014</LINK>; <LINK REF="REF-Malik-2000" TYPE="REFERENCE">Malik 2000</LINK>; <LINK REF="REF-Smith-2006" TYPE="REFERENCE">Smith 2006</LINK>). Alpha-lipoic acid has been shown to improve symptoms in diabetic polyneuropathy (<LINK REF="REF-Ziegler-2011" TYPE="REFERENCE">Ziegler 2011</LINK>). Vitamin B treatment for polyneuropathy is the subject of another Cochrane Review (<LINK REF="REF-Ang-2008" TYPE="REFERENCE">Ang 2008</LINK>).</P>
<P>Alternative approaches would be to test neurotrophic factors or strategies that improve the neuroprotective and neuroregenerative properties of Schwann cells (<LINK REF="REF-Fressinaud-2003" TYPE="REFERENCE">Fressinaud 2003</LINK>; <LINK REF="REF-Lehmann-2010" TYPE="REFERENCE">Lehmann 2010</LINK>; <LINK REF="REF-Leinninger-2004" TYPE="REFERENCE">Leinninger 2004</LINK>; <LINK REF="REF-Pradat-2003" TYPE="REFERENCE">Pradat 2003</LINK>; <LINK REF="REF-Sah-2003" TYPE="REFERENCE">Sah 2003</LINK>); another would be to test agents that have been shown to be effective in neurodegenerative conditions, for example riluzole, which increases survival time in motor neuron disease (<LINK REF="REF-Miller-2012" TYPE="REFERENCE">Miller 2012</LINK>). Neuroimmunophilin ligands such as tacrolimus derivatives without immunosuppressive properties, Rho kinase inhibitors, or neuroactive steroids also have neuroprotective and neuroregenerative activity (<LINK REF="REF-H_x00f6_ke-2005" TYPE="REFERENCE">Höke 2005</LINK>; <LINK REF="REF-M_x00fc_ller-2005" TYPE="REFERENCE">Müller 2005</LINK>; <LINK REF="REF-Roglio-2008" TYPE="REFERENCE">Roglio 2008</LINK>). During the processes of Wallerian degeneration, nitric oxide plays a central role and contributes to the development of neuropathic pain (<LINK REF="REF-Zochodne-2005" TYPE="REFERENCE">Zochodne 2005</LINK>). Thus, hypothetically, agents that prevent nitric oxide formation such as nitric oxide synthase inhibitors may form treatment options in the future, but no studies to date have investigated their possible clinical usefulness.</P>
<P>Without drug therapies that prevent progression, clinicians and patients must resort to symptomatic treatments. Pain can be a prominent feature in people with CIAP (<LINK REF="REF-Erdmann-2010" TYPE="REFERENCE">Erdmann 2010</LINK>). Treatment of neuropathic pain is the subject of various systematic reviews and meta-analyses, including Cochrane Reviews (<LINK REF="REF-Challapalli-2005" TYPE="REFERENCE">Challapalli 2005</LINK>; <LINK REF="REF-Chaparro-2012" TYPE="REFERENCE">Chaparro 2012</LINK>; <LINK REF="REF-Derry-2013" TYPE="REFERENCE">Derry 2013</LINK>; <LINK REF="REF-Derry-2015" TYPE="REFERENCE">Derry 2015</LINK>; <LINK REF="REF-Duehmke-2006" TYPE="REFERENCE">Duehmke 2006</LINK>; <LINK REF="REF-Finnerup-2015" TYPE="REFERENCE">Finnerup 2015</LINK>; <LINK REF="REF-McNicol-2013" TYPE="REFERENCE">McNicol 2013</LINK>; <LINK REF="REF-Moore-2015a" TYPE="REFERENCE">Moore 2015a</LINK>; <LINK REF="REF-Moore-2015b" TYPE="REFERENCE">Moore 2015b</LINK>; <LINK REF="REF-Moore-2015c" TYPE="REFERENCE">Moore 2015c</LINK>; <LINK REF="REF-Thompson-2015" TYPE="REFERENCE">Thompson 2015</LINK>; <LINK REF="REF-Wiffen-2013" TYPE="REFERENCE">Wiffen 2013</LINK>; <LINK REF="REF-Wiffen-2014" TYPE="REFERENCE">Wiffen 2014</LINK>; <LINK REF="REF-Wiffen-2015" TYPE="REFERENCE">Wiffen 2015</LINK>; <LINK REF="REF-Wrzosek-2015" TYPE="REFERENCE">Wrzosek 2015</LINK>), and evidence-based guidelines including the cost-effectiveness of therapy have been proposed (<LINK REF="REF-Attal-2010" TYPE="REFERENCE">Attal 2010</LINK>; <LINK REF="REF-Attal-2015" TYPE="REFERENCE">Attal 2015</LINK>; <LINK REF="REF-Cepeda-2006" TYPE="REFERENCE">Cepeda 2006</LINK>; <LINK REF="REF-Smith-2013" TYPE="REFERENCE">Smith 2013</LINK> ). With increased understanding of the role of ion channels in neuropathic pain, new therapeutic agents aimed at these ion channels are emerging and could be worth considering (<LINK REF="REF-Cohen-2014" TYPE="REFERENCE">Cohen 2014</LINK>; <LINK REF="REF-Gilron-2014" TYPE="REFERENCE">Gilron 2014</LINK>; <LINK REF="REF-Markman-2006" TYPE="REFERENCE">Markman 2006</LINK>).</P>
<P>Some people have foot drop, for which ankle-foot orthoses and other rehabilitative measures can be useful. The effect of exercise in peripheral neuropathy is the subject of a recent review and a Cochrane Review (<LINK REF="REF-Streckmann-2014" TYPE="REFERENCE">Streckmann 2014</LINK>; <LINK REF="REF-White-2004" TYPE="REFERENCE">White 2004</LINK>), and another Cochrane Review has also evaluated interventions for fatigue (<LINK REF="REF-White-2014" TYPE="REFERENCE">White 2014</LINK>). Effective methods for offering advice about foot care would also be worth considering since analgesia of the feet is a common feature.</P>
<P>The slow progression and mild disability produced by CIAP make it difficult to design adequate clinical trials. We recommend selecting a sensitive disability outcome measure as being more directly relevant to people's needs than an electrophysiological, pathological or impairment measure. Even though we preferred the modified Rankin scale for this review, a scale with more steps that is designed for measuring disability in peripheral neuropathy might be superior. Investigators should consider disability scores designed to measure upper- and lower-limb disability that have been validated for assessing change and reflect people's judgment in inflammatory neuropathies (<LINK REF="REF-Graham-2006a" TYPE="REFERENCE">Graham 2006a</LINK>; <LINK REF="REF-Merkies-2006" TYPE="REFERENCE">Merkies 2006</LINK>). Alternatively, since most people with CIAP experience difficulty walking, a scale that has been validated for evaluating walking disability in peripheral neuropathy would be useful (<LINK REF="REF-Graham-2006b" TYPE="REFERENCE">Graham 2006b</LINK>). Although the time frame for measurements of outcomes cannot be known with certainty, clinical follow-up in people with CIAP demonstrated stabilisation within the first five years after disease onset (<LINK REF="REF-Dyck-1981" TYPE="REFERENCE">Dyck 1981</LINK>; <LINK REF="REF-McLeod-1984" TYPE="REFERENCE">McLeod 1984</LINK>; <LINK REF="REF-Grahmann-1991" TYPE="REFERENCE">Grahmann 1991</LINK>; <LINK REF="REF-Notermans-1994" TYPE="REFERENCE">Notermans 1994</LINK>; <LINK REF="REF-Jann-2001" TYPE="REFERENCE">Jann 2001</LINK>; <LINK REF="REF-Vrancken-2002a" TYPE="REFERENCE">Vrancken 2002a</LINK>). Because of its slow progression, change in outcome measures will need to be assessed after long time intervals, for example after at least one and preferably two or three years. Since the disability produced by CIAP is mild and therapy is likely to be needed over a long period of time, it will be particularly important to identify inexpensive treatments that are not hampered by serious side effects.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2017-05-12 14:42:25 +0100" MODIFIED_BY="Ruth Brassington">
<IMPLICATIONS_PRACTICE MODIFIED="2017-05-12 14:42:25 +0100" MODIFIED_BY="Ruth Brassington">
<P>There are no randomised trials on which to base drug treatment for chronic idiopathic axonal polyneuropathy (CIAP).</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-04-11 23:47:25 +0100" MODIFIED_BY="Ruth Brassington">
<P>More research is needed on drug treatment for CIAP. Randomised trials will need to be long term and use sensitive outcome measures.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2017-05-10 16:23:52 +0100" MODIFIED_BY="Ruth Brassington">
<P>This project was supported by the National Institute for Health Research (NIHR) via Cochrane Infrastructure funding to Cochrane Neuromuscular. The views and opinions expressed herein are those of the review authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service, or the Department of Health. Cochrane Neuromuscular is also supported by the MRC Centre for Neuromuscular Diseases.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-06-13 12:21:57 +0100" MODIFIED_BY="Ruth Brassington">
<P>Janna Warendorf: none known.</P>
<P>Alexander Vranken: none known.</P>
<P>Ivo van Schaik: received departmental honoraria for serving on scientific advisory boards for CSL-Behring, Baxter and UCB, and a speaker's fee from Kedrion and CSL-Behring. He chairs a steering committee for CSL-Behring.</P>
<P>Richard Hughes: none known.</P>
<P>Nicolette Notermans: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2017-03-17 10:06:09 +0000" MODIFIED_BY="Ruth Brassington">
<P>Alexander Vrancken extracted the data and wrote the first draft. Ivo van Schaik and Janna Warendorf also extracted data. All authors contributed to subsequent drafts and agreed the final version.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2017-05-12 12:29:52 +0100" MODIFIED_BY="Ruth Brassington">
<P>We revised the risk of bias methods section according to the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>We included methods for creating 'Summary of findings' tables.</P>
<P>We no longer search the American College of Physicians (ACP) Journal Club, which was listed in the protocol (<LINK REF="REF-Vrancken-2002b" TYPE="REFERENCE">Vrancken 2002b</LINK>), as the search has not yielded useful results. We included searches of clinical trials registries.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2017-06-13 12:21:59 +0100" MODIFIED_BY="Ruth Brassington">
<P>In 2016 the review authors incorporated new searches. As the review has no included trials, the review underwent minor revisions without comprehensive application of current standards. New evidence on this topic is slow to emerge. The next update is planned for 2020, which is four years after the last search rather than the usual two years. If new trials are published in the interim we will schedule an earlier update.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-06-13 12:27:15 +0100" MODIFIED_BY="Ruth Brassington">
<STUDIES MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington">
<INCLUDED_STUDIES MODIFIED="2016-07-06 14:57:59 +0100" MODIFIED_BY="[Empty name]"/>
<EXCLUDED_STUDIES MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington">
<STUDY DATA_SOURCE="PUB" ID="STD-Attal-2016" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Attal 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Attal N, de Andrade DC, Adam F</AU>
<TI>Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial</TI>
<SO>Lancet Neurology</SO>
<YR>2016</YR>
<VL>15</VL>
<NO>6</NO>
<PG>555-65</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5748178"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5748177"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bradley-1988" MODIFIED="2011-04-07 11:05:50 +0100" MODIFIED_BY="Ruth Brassington" NAME="Bradley 1988" YEAR="1988">
<REFERENCE MODIFIED="2011-04-07 11:05:50 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bradley WG, Badger GJ, Tandan R, Fillyaw MJ, Young J, Fries TJ, et al</AU>
<TI>Double-blind controlled trials of Cronassial in chronic neuromuscular diseases and ataxia</TI>
<SO>Neurology</SO>
<YR>1988</YR>
<VL>38</VL>
<NO>11</NO>
<PG>1731-9</PG>
<IDENTIFIERS MODIFIED="2011-04-07 11:05:50 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892353"/><IDENTIFIER MODIFIED="2011-04-07 11:05:45 +0100" MODIFIED_BY="Ruth Brassington" TYPE="PUBMED" VALUE="2847079"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892352"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Grandis-1995" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="De Grandis 1995" YEAR="1995">
<REFERENCE MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Grandis D, Santoro L, Di Benedetto P</AU>
<TI>L-acetylcarnitine in the treatment of patients with peripheral neuropathies: a short term, double-blind clinical study of 426 patients</TI>
<SO>Clinical Drug Investigation</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>6</NO>
<PG>317-22</PG>
<IDENTIFIERS MODIFIED="2010-11-16 23:05:31 +0000" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892355"/><IDENTIFIER MODIFIED="2010-11-16 23:05:31 +0000" MODIFIED_BY="Alexander FJE Vrancken" TYPE="EMBASE" VALUE="1996006029"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892354"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Demant-2014" MODIFIED="2017-03-17 10:03:16 +0000" MODIFIED_BY="Ruth Brassington" NAME="Demant 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-03-17 10:03:16 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Demant DT, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup NB, et al</AU>
<TI>The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study</TI>
<SO>Pain</SO>
<YR>2014</YR>
<VL>155</VL>
<NO>11</NO>
<PG>2263-73</PG>
<IDENTIFIERS MODIFIED="2016-02-10 16:42:16 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892357"/><IDENTIFIER MODIFIED="2016-02-10 16:42:16 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="25139589"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892356"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frank-2008" MODIFIED="2011-04-04 15:15:23 +0100" MODIFIED_BY="Ruth Brassington" NAME="Frank 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-04-04 15:15:23 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D</AU>
<TI>Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7637</NO>
<PG>199-201</PG>
<IDENTIFIERS MODIFIED="2011-04-04 15:15:23 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892359"/><IDENTIFIER MODIFIED="2011-04-04 15:15:20 +0100" MODIFIED_BY="Ruth Brassington" TYPE="PUBMED" VALUE="18182416"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892358"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galer-2000" MODIFIED="2010-11-16 22:48:41 +0000" MODIFIED_BY="Alexander FJE Vrancken" NAME="Galer 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-11-16 22:48:41 +0000" MODIFIED_BY="Alexander FJE Vrancken" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galer BS, Twilling LL, Harle J, Cluff RS, Friedman E, Rowbotham MC</AU>
<TI>Lack of efficacy of riluzole in the treatment of peripheral neuropathic pain conditions</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>7</NO>
<PG>971-5</PG>
<IDENTIFIERS MODIFIED="2010-11-16 22:48:41 +0000" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892361"/><IDENTIFIER MODIFIED="2010-11-16 22:48:41 +0000" MODIFIED_BY="Alexander FJE Vrancken" TYPE="PUBMED" VALUE="11061253"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892360"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gilron-2011" MODIFIED="2017-03-17 10:02:54 +0000" MODIFIED_BY="Ruth Brassington" NAME="Gilron 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-03-17 10:02:54 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gilron I, Wajsbrot D, Therrien F, Lemay J</AU>
<TI>Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial</TI>
<SO>Clinical Journal of Pain</SO>
<YR>2011</YR>
<VL>27</VL>
<NO>3</NO>
<PG>185-93</PG>
<IDENTIFIERS MODIFIED="2016-02-10 15:40:20 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892363"/><IDENTIFIER MODIFIED="2016-02-10 15:40:20 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21178603"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892362"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haanpaa-2016" MODIFIED="2017-05-12 12:33:44 +0100" MODIFIED_BY="Ruth Brassington" NAME="Haanpaa 2016" YEAR="2016">
<REFERENCE MODIFIED="2017-05-12 12:33:44 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haanpää M, Cruccu G, Nurmikko TJ, McBride WT, Docu Axelarad A, Bosilkov A, et al</AU>
<TI>Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain</TI>
<SO>European Journal of Pain</SO>
<YR>2016</YR>
<VL>20</VL>
<NO>2</NO>
<PG>316-28</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5748180"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5748179"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hewitt-2011" MODIFIED="2017-03-17 10:02:42 +0000" MODIFIED_BY="Ruth Brassington" NAME="Hewitt 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-03-17 10:02:42 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hewitt DJ, Ho TW, Galer B, Backonja M, Markovitz P, Gammaitoni A, et al</AU>
<TI>Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain</TI>
<SO>Pain</SO>
<YR>2011</YR>
<VL>152</VL>
<NO>3</NO>
<PG>514-21</PG>
<IDENTIFIERS MODIFIED="2016-02-10 16:19:38 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892365"/><IDENTIFIER MODIFIED="2016-02-10 16:19:38 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21185118"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892364"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ho-2008" MODIFIED="2011-02-15 11:14:39 +0000" MODIFIED_BY="[Empty name]" NAME="Ho 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-02-15 11:14:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ho KY, Huh BK, White WD, Yeh CC, Miller EJ</AU>
<TI>Topical amitriptyline versus lidocaine in the treatment of neuropathic pain</TI>
<SO>The Clinical Journal of Pain</SO>
<YR>2008</YR>
<VL>24</VL>
<NO>1</NO>
<PG>51-5</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:01:21 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892367"/><IDENTIFIER TYPE="PUBMED" VALUE="18180637"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892366"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ho-2009" MODIFIED="2010-11-16 21:59:17 +0000" MODIFIED_BY="Alexander FJE Vrancken" NAME="Ho 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-11-16 21:59:17 +0000" MODIFIED_BY="Alexander FJE Vrancken" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ho TW, Backonja M, Ma J, Leibensperger H, Froman S, Polydefkis M</AU>
<TI>Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies</TI>
<SO>Pain</SO>
<YR>2009</YR>
<VL>141</VL>
<NO>1-2</NO>
<PG>19-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892369"/><IDENTIFIER TYPE="PUBMED" VALUE="19013718"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892368"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holbech-2011" MODIFIED="2017-03-17 10:02:23 +0000" MODIFIED_BY="Ruth Brassington" NAME="Holbech 2011" YEAR="2011">
<REFERENCE MODIFIED="2017-03-17 10:02:23 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holbech JV, Otto M, Bach FW, Jensen TS, Sindrup SH</AU>
<TI>The anticonvulsant levetiracetam for the treatment of pain in polyneuropathy: a randomized, placebo-controlled, cross-over trial</TI>
<SO>European Journal of Pain</SO>
<YR>2011</YR>
<VL>15</VL>
<NO>6</NO>
<PG>608-14</PG>
<IDENTIFIERS MODIFIED="2016-02-10 16:07:06 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892371"/><IDENTIFIER MODIFIED="2016-02-10 16:07:06 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21183370"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892370"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holbech-2015" MODIFIED="2017-04-03 15:59:07 +0100" MODIFIED_BY="Ruth Brassington" NAME="Holbech 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-04-03 15:59:07 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holbech JV, Bach FW, Finnerup NB, Brøsen K, Jensen TS, Sindrup SH</AU>
<TI>Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial</TI>
<SO>Pain</SO>
<YR>2015</YR>
<VL>156</VL>
<NO>5</NO>
<PG>958-66</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5748182"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-05-27 15:59:32 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5748181"/><IDENTIFIER MODIFIED="2016-05-27 15:57:05 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01047488"/><IDENTIFIER MODIFIED="2016-05-27 15:59:32 +0100" MODIFIED_BY="[Empty name]" OTHERTYPE="Pubmed" TYPE="OTHER" VALUE="25719617"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huge-2010" MODIFIED="2011-04-07 11:47:56 +0100" MODIFIED_BY="Ruth Brassington" NAME="Huge 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-04-07 11:47:56 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huge V, Lauchart M, Magerl W, Schelling G, Beyer A, Thieme D, et al</AU>
<TI>Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain</TI>
<SO>European Journal of Pain</SO>
<YR>2010</YR>
<VL>14</VL>
<NO>4</NO>
<PG>387-94</PG>
<IDENTIFIERS MODIFIED="2011-02-14 12:48:29 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892373"/><IDENTIFIER TYPE="PUBMED" VALUE="19733106"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892372"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Husstedt-1993" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Husstedt 1993" NOTES="&lt;p&gt;Issue no. not traceable&lt;/p&gt;" NOTES_MODIFIED="2017-06-13 12:26:06 +0100" NOTES_MODIFIED_BY="Ruth Brassington" YEAR="1993">
<REFERENCE MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Husstedt IW, Thümler R, Röder R, Dreyer M, Leopold W, Scheller W</AU>
<TI>Behandlung von Polyneuropathien. Untersuchungen zur Wirksamkeit von Ginkgo-biloba-Extrakt EGb 761 bei Patienten mit Polyneuropathie</TI>
<SO>Zeitschrift für Allgemeine Medizin</SO>
<YR>1993</YR>
<VL>69</VL>
<PG>714-7</PG>
<IDENTIFIERS MODIFIED="2010-11-16 23:07:35 +0000" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892375"/><IDENTIFIER MODIFIED="2010-11-16 23:07:35 +0000" MODIFIED_BY="Alexander FJE Vrancken" TYPE="EMBASE" VALUE="1993302831"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892374"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jensen-2012" MODIFIED="2017-03-17 10:00:33 +0000" MODIFIED_BY="Ruth Brassington" NAME="Jensen 2012" YEAR="2012">
<REFERENCE MODIFIED="2017-03-17 10:00:33 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jensen MP, Gammaitoni AR, Bolognese JA, Alon A, Smugar SS, Galer BS, et al</AU>
<TI>The pain quality response profile of pregabalin in the treatment of neuropathic pain</TI>
<SO>Clinical Journal of Pain</SO>
<YR>2012</YR>
<VL>28</VL>
<NO>8</NO>
<PG>683-6</PG>
<IDENTIFIERS MODIFIED="2016-02-10 16:13:39 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892377"/><IDENTIFIER MODIFIED="2016-02-10 16:13:39 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22156827"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892376"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kishore_x002d_Kumar-1989" MODIFIED="2010-11-16 23:11:46 +0000" MODIFIED_BY="Alexander FJE Vrancken" NAME="Kishore-Kumar 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-11-16 23:11:46 +0000" MODIFIED_BY="Alexander FJE Vrancken" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kishore-Kumar R, Schafer SC, Lawlor BA, Murphy DL, Max MB</AU>
<TI>Single doses of the serotonin agonists buspirone and m-chlorophenylpiperazine do not relieve neuropathic pain</TI>
<SO>Pain</SO>
<YR>1989</YR>
<VL>37</VL>
<NO>2</NO>
<PG>223-7</PG>
<IDENTIFIERS MODIFIED="2010-11-16 23:11:46 +0000" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892379"/><IDENTIFIER MODIFIED="2010-11-16 23:11:46 +0000" MODIFIED_BY="Alexander FJE Vrancken" TYPE="PUBMED" VALUE="2664664"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892378"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Langohr-1982" MODIFIED="2011-04-07 11:48:37 +0100" MODIFIED_BY="Ruth Brassington" NAME="Langohr 1982" YEAR="1982">
<REFERENCE MODIFIED="2011-04-07 11:48:37 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Langohr HD, Stohr M, Petruch F</AU>
<TI>An open and double-blind cross-over study on the efficacy of clomipramine (Anafranil) in patients with painful mono- and polyneuropathies</TI>
<SO>European Neurology</SO>
<YR>1982</YR>
<VL>21</VL>
<NO>5</NO>
<PG>309-17</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892381"/><IDENTIFIER TYPE="PUBMED" VALUE="6126361"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892380"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2010" MODIFIED="2011-04-07 11:48:57 +0100" MODIFIED_BY="Ruth Brassington" NAME="Li 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-04-07 11:48:57 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li L</AU>
<TI>The effect of Neuragen PN on neuropathic pain: a randomized, double blind, placebo controlled clinical trial</TI>
<SO>BMC Complementary and Alternative Medicine</SO>
<YR>2010</YR>
<VL>10</VL>
<PG>22</PG>
<IDENTIFIERS MODIFIED="2010-09-01 20:11:19 +0100" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892383"/><IDENTIFIER TYPE="PUBMED" VALUE="20487567"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892382"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Low-1995" MODIFIED="2010-11-16 23:13:20 +0000" MODIFIED_BY="Alexander FJE Vrancken" NAME="Low 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-11-16 23:13:20 +0000" MODIFIED_BY="Alexander FJE Vrancken" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Low PA, Opfer-Gehrking TL, Dyck PJ, Litchy WJ, O'Brien PC</AU>
<TI>Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy</TI>
<SO>Pain</SO>
<YR>1995</YR>
<VL>62</VL>
<NO>2</NO>
<PG>163-8</PG>
<IDENTIFIERS MODIFIED="2010-11-16 23:13:20 +0000" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892385"/><IDENTIFIER MODIFIED="2010-11-16 23:13:20 +0000" MODIFIED_BY="Alexander FJE Vrancken" TYPE="PUBMED" VALUE="8545141"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892384"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maier-2002" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Maier 2002" YEAR="2002">
<REFERENCE MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maier C, Hildebrandt J, Klinger R, Henrich-Ebert C, Lindena G, the MONTAS Study Group</AU>
<TI>Morphine responsiveness, efficacy and tolerability in patients with chronic no-tumor associated pain - results of a double-blind placebo-controlled trial (MONTAS)</TI>
<SO>Pain</SO>
<YR>2002</YR>
<VL>97</VL>
<NO>3</NO>
<PG>223-33</PG>
<IDENTIFIERS MODIFIED="2010-11-16 23:14:47 +0000" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892387"/><IDENTIFIER MODIFIED="2010-11-16 23:14:47 +0000" MODIFIED_BY="Alexander FJE Vrancken" TYPE="PUBMED" VALUE="12044619"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892386"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meier-2003" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Meier 2003" YEAR="2003">
<REFERENCE MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meier T, Wasner G, Faust M, Kuntzer T, Ochsner F, Hueppe M, et al</AU>
<TI>Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study</TI>
<SO>Pain</SO>
<YR>2003</YR>
<VL>106</VL>
<NO>1-2</NO>
<PG>151-8</PG>
<IDENTIFIERS MODIFIED="2010-11-16 23:33:22 +0000" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892389"/><IDENTIFIER MODIFIED="2010-11-16 23:33:22 +0000" MODIFIED_BY="Alexander FJE Vrancken" TYPE="PUBMED" VALUE="14581122"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892388"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morley-2003" MODIFIED="2017-06-13 12:24:55 +0100" MODIFIED_BY="Ruth Brassington" NAME="Morley 2003" YEAR="2003">
<REFERENCE MODIFIED="2017-06-13 12:24:55 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morley JS, Bridson J, Nash TP, Miles JB, White S, Makin MK</AU>
<TI>Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled crossover trial</TI>
<SO>Palliative Medicine</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>7</NO>
<PG>576-87</PG>
<IDENTIFIERS MODIFIED="2010-11-16 23:37:51 +0000" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892391"/><IDENTIFIER MODIFIED="2010-11-16 23:37:51 +0000" MODIFIED_BY="Alexander FJE Vrancken" TYPE="PUBMED" VALUE="14594148"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892390"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-NCT00156689" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="NCT00156689" YEAR="2008">
<REFERENCE MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00156689</AU>
<TI>A study to determine if levetiracetam will assist those suffering from chronic idiopathic axonal polyneuropathy</TI>
<TO>A pilot study in a double blind, randomized, placebo-controlled, parallel-group, 16 week, trial design evaluating the efficacy and safety of levetiracetam 500 mg tablets in bid administration (daily dose ranging from 1000 mg to 3000 mg), in adults (&gt;18 years of ages) suffering from chronic idiopathic axonal polyneuropathy</TO>
<SO>clinicaltrials.gov/ct2/show/NCT00156689</SO>
<YR>(first received 7 September 2005)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5748184"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-03-17 10:05:29 +0000" MODIFIED_BY="Ruth Brassington"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5748183"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nurmikko-2007" MODIFIED="2010-11-16 21:29:39 +0000" MODIFIED_BY="Alexander FJE Vrancken" NAME="Nurmikko 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-16 21:29:39 +0000" MODIFIED_BY="Alexander FJE Vrancken" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D</AU>
<TI>Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial</TI>
<SO>Pain</SO>
<YR>2007</YR>
<VL>133</VL>
<NO>1-3</NO>
<PG>210-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892393"/><IDENTIFIER TYPE="PUBMED" VALUE="17997224"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892392"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Onofrj-1995" MODIFIED="2010-11-16 23:50:28 +0000" MODIFIED_BY="Alexander FJE Vrancken" NAME="Onofrj 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-11-16 23:50:28 +0000" MODIFIED_BY="Alexander FJE Vrancken" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Onofrj M, Fulgente T, Melchionda D, Marchionni A, Tomasello F, Salpietro FM, et al</AU>
<TI>L-acetylcarnitine as a new therapeutic approach for peripheral neuropathies with pain</TI>
<SO>International Journal of Clinical Pharmacology Research</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>1</NO>
<PG>9-15</PG>
<IDENTIFIERS MODIFIED="2010-11-16 23:50:28 +0000" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892395"/><IDENTIFIER MODIFIED="2010-11-16 23:50:28 +0000" MODIFIED_BY="Alexander FJE Vrancken" TYPE="PUBMED" VALUE="7490173"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892394"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Otto-2004" MODIFIED="2010-11-16 23:52:08 +0000" MODIFIED_BY="Alexander FJE Vrancken" NAME="Otto 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-11-16 23:52:08 +0000" MODIFIED_BY="Alexander FJE Vrancken" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Otto M, Bach FW, Jensen TS, Sindrup SH</AU>
<TI>Valproic acid has no effect in polyneuropathy. A randomized, controlled trial</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>62</VL>
<NO>2</NO>
<PG>285-8</PG>
<IDENTIFIERS MODIFIED="2010-11-16 23:52:08 +0000" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892397"/><IDENTIFIER MODIFIED="2010-11-16 23:52:08 +0000" MODIFIED_BY="Alexander FJE Vrancken" TYPE="PUBMED" VALUE="14745070"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892396"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Otto-2008" MODIFIED="2011-04-07 11:50:05 +0100" MODIFIED_BY="Ruth Brassington" NAME="Otto 2008" YEAR="2009">
<REFERENCE MODIFIED="2011-04-07 11:50:05 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Otto M, Bach FW, Jensen TS, Brøsen K, Sindrup SH</AU>
<TI>Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial</TI>
<SO>Pain</SO>
<YR>2008</YR>
<VL>139</VL>
<NO>2</NO>
<PG>275-83</PG>
<IDENTIFIERS MODIFIED="2010-09-01 20:11:19 +0100" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892399"/><IDENTIFIER TYPE="PUBMED" VALUE="18547727"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892398"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pedersen-2014" MODIFIED="2017-03-17 10:00:07 +0000" MODIFIED_BY="Ruth Brassington" NAME="Pedersen 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-03-17 10:00:07 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pedersen L, Borchgrevink PC, Breivik HP, Fredheim OM</AU>
<TI>A randomized, double-blind, double-dummy comparison of short- and long-acting dihydrocodeine in chronic non-malignant pain</TI>
<SO>Pain</SO>
<YR>2014</YR>
<VL>155</VL>
<NO>5</NO>
<PG>881-8</PG>
<IDENTIFIERS MODIFIED="2016-02-10 15:59:12 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892401"/><IDENTIFIER MODIFIED="2016-02-10 15:59:12 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24345428"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892400"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raber-2015" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Raber 2015" YEAR="2015">
<REFERENCE MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raber JM, Reichelt D, Gruneberg-oelker U, Phillipp K, Stubbe-Drager B, Husstedt I</AU>
<TI>Capsaicin 8% as a cutaneous patch (Qutenza&#8482;): analgesic effect on patients with peripheral neuropathic pain</TI>
<SO>Acta Neurological Belgica</SO>
<YR>2015</YR>
<VL>115</VL>
<NO>3</NO>
<PG>335-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5748186"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5748185"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rauck-2006" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Rauck 2006" YEAR="2006">
<REFERENCE MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rauck RL, Wallace MS, Leong MS, MineHart M, Webster LR, Charapata SG, et al; Ziconotide Study Group</AU>
<TI>A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>5</NO>
<PG>393-406</PG>
<IDENTIFIERS MODIFIED="2010-11-16 23:55:35 +0000" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892403"/><IDENTIFIER MODIFIED="2010-11-16 23:55:35 +0000" MODIFIED_BY="Alexander FJE Vrancken" TYPE="PUBMED" VALUE="16716870"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892402"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rowbotham-2003" MODIFIED="2010-11-16 23:57:55 +0000" MODIFIED_BY="Alexander FJE Vrancken" NAME="Rowbotham 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-11-16 23:57:55 +0000" MODIFIED_BY="Alexander FJE Vrancken" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D</AU>
<TI>Oral opioid therapy for chronic peripheral and central neuropathic pain</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>348</VL>
<NO>13</NO>
<PG>1223-32</PG>
<IDENTIFIERS MODIFIED="2010-11-16 23:57:55 +0000" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892405"/><IDENTIFIER MODIFIED="2010-11-16 23:57:55 +0000" MODIFIED_BY="Alexander FJE Vrancken" TYPE="PUBMED" VALUE="12660386"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892404"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Semenchuk-2001" MODIFIED="2017-04-03 15:59:07 +0100" MODIFIED_BY="Ruth Brassington" NAME="Semenchuk 2001" YEAR="2001">
<REFERENCE MODIFIED="2017-04-03 15:59:07 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Semenchuk MR, Sherman S, Davis B</AU>
<TI>Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>9</NO>
<PG>1583-8</PG>
<IDENTIFIERS MODIFIED="2010-11-17 00:03:42 +0000" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892407"/><IDENTIFIER MODIFIED="2010-11-17 00:03:42 +0000" MODIFIED_BY="Alexander FJE Vrancken" TYPE="PUBMED" VALUE="11706096"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892406"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serpell-2014" MODIFIED="2017-03-17 09:59:56 +0000" MODIFIED_BY="Ruth Brassington" NAME="Serpell 2014" YEAR="2014">
<REFERENCE MODIFIED="2017-03-17 09:59:56 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, et al</AU>
<TI>A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment</TI>
<SO>European Journal of Pain</SO>
<YR>2014</YR>
<VL>18</VL>
<NO>7</NO>
<PG>999-1012</PG>
<IDENTIFIERS MODIFIED="2016-02-10 16:33:30 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892409"/><IDENTIFIER MODIFIED="2016-02-10 16:33:30 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24420962"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892408"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sindrup-1999a" MODIFIED="2010-11-17 00:13:30 +0000" MODIFIED_BY="Alexander FJE Vrancken" NAME="Sindrup 1999a" YEAR="1999">
<REFERENCE MODIFIED="2010-11-17 00:13:30 +0000" MODIFIED_BY="Alexander FJE Vrancken" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sindrup SH, Andersen G, Madsen C, Smith T, Brosen K, Jensen TS</AU>
<TI>Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial</TI>
<SO>Pain</SO>
<YR>1999</YR>
<VL>83</VL>
<NO>1</NO>
<PG>85-90</PG>
<IDENTIFIERS MODIFIED="2010-11-17 00:13:30 +0000" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892411"/><IDENTIFIER MODIFIED="2010-11-17 00:13:30 +0000" MODIFIED_BY="Alexander FJE Vrancken" TYPE="PUBMED" VALUE="10506675"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892410"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sindrup-1999b" MODIFIED="2011-02-14 13:47:12 +0000" MODIFIED_BY="[Empty name]" NAME="Sindrup 1999b" YEAR="1999">
<REFERENCE MODIFIED="2010-11-17 00:14:10 +0000" MODIFIED_BY="Alexander FJE Vrancken" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sindrup SH, Madsen C, Brosen K, Jensen TS</AU>
<TI>The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1999</YR>
<VL>66</VL>
<NO>6</NO>
<PG>636-41</PG>
<IDENTIFIERS MODIFIED="2010-11-17 00:14:10 +0000" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892413"/><IDENTIFIER MODIFIED="2010-11-17 00:14:10 +0000" MODIFIED_BY="Alexander FJE Vrancken" TYPE="PUBMED" VALUE="10613620"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892412"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sindrup-2001" MODIFIED="2010-11-17 00:14:42 +0000" MODIFIED_BY="Alexander FJE Vrancken" NAME="Sindrup 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-11-17 00:14:42 +0000" MODIFIED_BY="Alexander FJE Vrancken" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sindrup SH, Madsen C, Bach FW, Gram LF, Jensen TS</AU>
<TI>St. John's wort has no effect on pain in polyneuropathy</TI>
<SO>Pain</SO>
<YR>2001</YR>
<VL>91</VL>
<NO>3</NO>
<PG>361-5</PG>
<IDENTIFIERS MODIFIED="2010-11-17 00:14:42 +0000" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892415"/><IDENTIFIER MODIFIED="2010-11-17 00:14:42 +0000" MODIFIED_BY="Alexander FJE Vrancken" TYPE="PUBMED" VALUE="11275394 "/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892414"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sindrup-2003" MODIFIED="2010-11-17 00:15:13 +0000" MODIFIED_BY="Alexander FJE Vrancken" NAME="Sindrup 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-11-17 00:15:13 +0000" MODIFIED_BY="Alexander FJE Vrancken" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS</AU>
<TI>Venlafaxine versus imipramine in painful polyneuropathy</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>8</NO>
<PG>1284-9</PG>
<IDENTIFIERS MODIFIED="2010-11-17 00:15:13 +0000" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892417"/><IDENTIFIER MODIFIED="2010-11-17 00:15:13 +0000" MODIFIED_BY="Alexander FJE Vrancken" TYPE="PUBMED" VALUE="12707430"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892416"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sindrup-2012" MODIFIED="2017-03-17 09:59:43 +0000" MODIFIED_BY="Ruth Brassington" NAME="Sindrup 2012" YEAR="2012">
<REFERENCE MODIFIED="2017-03-17 09:59:43 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sindrup SH, Konder R, Lehmann R, Meier T, Winkel M, Ashworth J, et al</AU>
<TI>Randomized controlled trial of the combined monoaminergic and opioid investigational compound GRT9906 in painful polyneuropathy</TI>
<SO>European Journal of Pain</SO>
<YR>2012</YR>
<VL>16</VL>
<NO>6</NO>
<PG>849-59</PG>
<IDENTIFIERS MODIFIED="2016-02-10 16:03:03 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892419"/><IDENTIFIER MODIFIED="2016-02-10 16:03:03 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22337471"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892418"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vrethem-1997" MODIFIED="2010-11-17 00:20:21 +0000" MODIFIED_BY="Alexander FJE Vrancken" NAME="Vrethem 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-11-17 00:20:21 +0000" MODIFIED_BY="Alexander FJE Vrancken" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vrethem M, Boivie J, Arnqvist H, Holmgren H, Lindstrom T, Thorell</AU>
<TI>A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics</TI>
<SO>Clinical Journal of Pain</SO>
<YR>1997</YR>
<VL>13</VL>
<NO>4</NO>
<PG>313-23</PG>
<IDENTIFIERS MODIFIED="2010-11-17 00:20:21 +0000" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892421"/><IDENTIFIER MODIFIED="2010-11-17 00:20:21 +0000" MODIFIED_BY="Alexander FJE Vrancken" TYPE="PUBMED" VALUE="9430812"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892420"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wallace-2000" MODIFIED="2011-04-07 11:06:09 +0100" MODIFIED_BY="Ruth Brassington" NAME="Wallace 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-04-07 11:06:09 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wallace MS, Magnuson S, Ridgeway B</AU>
<TI>Efficacy of oral mexiletine for neuropathic pain with allodynia: a double-blind, placebo-controlled, crossover study</TI>
<SO>Regional Anesthesia and Pain Medicine</SO>
<YR>2000</YR>
<VL>25</VL>
<NO>5</NO>
<PG>459-67</PG>
<IDENTIFIERS MODIFIED="2010-11-17 00:23:01 +0000" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892423"/><IDENTIFIER MODIFIED="2010-11-17 00:23:01 +0000" MODIFIED_BY="Alexander FJE Vrancken" TYPE="PUBMED" VALUE="11009230"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892422"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wallace-2002" MODIFIED="2010-11-17 00:26:04 +0000" MODIFIED_BY="Alexander FJE Vrancken" NAME="Wallace 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-11-17 00:26:04 +0000" MODIFIED_BY="Alexander FJE Vrancken" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wallace MS, Rowbotham M, Bennett GJ, Jensen TS, Pladna R, Quessy S</AU>
<TI>A multicenter, double-blind, randomized, placebo-controlled crossover evaluation of a short course of 4030W92 in patients with chronic neuropathic pain</TI>
<SO>Journal of Pain</SO>
<YR>2002</YR>
<VL>3</VL>
<NO>3</NO>
<PG>227-33</PG>
<IDENTIFIERS MODIFIED="2010-11-17 00:26:04 +0000" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892425"/><IDENTIFIER MODIFIED="2010-11-17 00:26:04 +0000" MODIFIED_BY="Alexander FJE Vrancken" TYPE="PUBMED" VALUE="14622777"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892424"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilsey-2013" MODIFIED="2017-03-17 10:03:33 +0000" MODIFIED_BY="Ruth Brassington" NAME="Wilsey 2013" YEAR="2013">
<REFERENCE MODIFIED="2017-03-17 10:03:33 +0000" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H</AU>
<TI>Low-dose vaporized cannabis significantly improves neuropathic pain</TI>
<SO>Journal of Pain</SO>
<YR>2013</YR>
<VL>14</VL>
<NO>2</NO>
<PG>136-48</PG>
<IDENTIFIERS MODIFIED="2016-02-10 16:29:22 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892427"/><IDENTIFIER MODIFIED="2016-02-10 16:29:22 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23237736"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892426"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Windebank-2004" MODIFIED="2010-11-17 00:29:34 +0000" MODIFIED_BY="Alexander FJE Vrancken" NAME="Windebank 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-11-17 00:29:34 +0000" MODIFIED_BY="Alexander FJE Vrancken" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Windebank AJ, Sorenson EJ, Civil R, O'Brien PC</AU>
<TI>Role of insulin-like growth factor-I in the treatment of painful small fiber predominant neuropathy</TI>
<SO>Journal of the Peripheral Nervous System</SO>
<YR>2004</YR>
<VL>9</VL>
<PG>183-9</PG>
<IDENTIFIERS MODIFIED="2010-11-17 00:29:34 +0000" MODIFIED_BY="Alexander FJE Vrancken"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2892429"/><IDENTIFIER MODIFIED="2010-11-17 00:29:34 +0000" MODIFIED_BY="Alexander FJE Vrancken" TYPE="PUBMED" VALUE="15363067"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2892428"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-11-16 22:31:19 +0000" MODIFIED_BY="Alexander FJE Vrancken"/>
<ONGOING_STUDIES MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington">
<STUDY DATA_SOURCE="PUB" ID="STD-NCT02260388" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="NCT02260388" YEAR="">
<REFERENCE MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02260388</AU>
<TI>Patient assisted intervention for neuropathy: comparison of treatment in real life situations (PAIN-CONTRoLS)</TI>
<SO>clinicaltrials.gov/ct2/show/NCT02260388</SO>
<YR>(first received 6 October 2014)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5748188"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5748187"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT02597257" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="NCT02597257" YEAR="">
<REFERENCE MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="OTHER">
<TI>Efficacy and safety of lidocaine infusion treatment in management of neuropathic pain: randomized, controlled, comparative study</TI>
<TO>Efficacy and safety of lidocaine infusion treatment in management of neuropathic pain</TO>
<SO>clinicaltrials.gov/ct2/show/NCT02597257</SO>
<YR>(first received 18 September 2015)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5748190"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5748189"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington">
<ADDITIONAL_REFERENCES MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington">
<REFERENCE ID="REF-Ang-2008" MODIFIED="2016-04-12 00:00:22 +0100" MODIFIED_BY="Ruth Brassington" NAME="Ang 2008" TYPE="COCHRANE_REVIEW">
<AU>Ang CD, Alviar MJ, Dans AL, Bautista-Velez GG, Villaruz-Sulit MV, Tan JJ, et al</AU>
<TI>Vitamin B for treating peripheral neuropathy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2016-04-12 00:00:11 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2016-04-12 00:00:11 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD004573.pub3"/><IDENTIFIER MODIFIED="2016-04-11 23:59:45 +0100" MODIFIED_BY="Ruth Brassington" TYPE="PUBMED" VALUE="18646107"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Attal-2010" MODIFIED="2010-08-24 17:06:07 +0100" MODIFIED_BY="Alexander FJE Vrancken" NAME="Attal 2010" TYPE="JOURNAL_ARTICLE">
<AU>Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, et al</AU>
<TI>EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision</TI>
<SO>European Journal of Neurology</SO>
<YR>2010</YR>
<VL>17</VL>
<NO>9</NO>
<PG>1113-e88</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="20402746"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Attal-2015" MODIFIED="2016-02-15 09:55:31 +0000" MODIFIED_BY="[Empty name]" NAME="Attal 2015" TYPE="JOURNAL_ARTICLE">
<AU>Attal N, Bouhassira D</AU>
<TI>Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms?</TI>
<SO>Pain</SO>
<YR>2015</YR>
<VL>156 Suppl 1</VL>
<PG>S104-14</PG>
<IDENTIFIERS MODIFIED="2016-02-15 09:55:29 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="25789426"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Baldereschi-2013" MODIFIED="2016-04-12 13:01:50 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Baldereschi 2013" TYPE="JOURNAL_ARTICLE">
<AU>Baldereschi M, Inzitari M, Di Carlo A, Bovis F, Maggi S, Capurso A, et al</AU>
<TI>Vascular factors predict polyneuropathy in a non-diabetic elderly population</TI>
<SO>Neurological Sciences</SO>
<YR>2013</YR>
<VL>34</VL>
<NO>6</NO>
<PG>955-62</PG>
<IDENTIFIERS MODIFIED="2016-02-12 15:39:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="22893359"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bays-2006" MODIFIED="2016-04-12 13:01:40 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Bays 2006" TYPE="JOURNAL_ARTICLE">
<AU>Bays H</AU>
<TI>Statin safety: an overview and assessment of the data--2005</TI>
<SO>American Journal of Cardiology</SO>
<YR>2006</YR>
<VL>97</VL>
<NO>8A</NO>
<PG>6C-26C</PG>
<IDENTIFIERS MODIFIED="2016-02-12 15:39:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="16581330"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bhalla-2014" MODIFIED="2016-04-12 13:01:28 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Bhalla 2014" TYPE="JOURNAL_ARTICLE">
<AU>Bhalla S, Singh N, Jaggi AS</AU>
<TI>Statins: do they aggravate or ameliorate neuropathic pain?</TI>
<SO>Journal of Pain</SO>
<YR>2014</YR>
<VL>15</VL>
<NO>11</NO>
<PG>1069-80</PG>
<IDENTIFIERS MODIFIED="2016-02-12 15:39:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="25086324"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Camerlingo-1998" MODIFIED="2011-04-07 11:06:54 +0100" MODIFIED_BY="Ruth Brassington" NAME="Camerlingo 1998" TYPE="JOURNAL_ARTICLE">
<AU>Camerlingo M, Nemni R, Ferraro B, Casto L, Partziguian T, Censori B, et al</AU>
<TI>Malignancy and sensory neuropathy of unexplained cause: a prospective study of 51 patients</TI>
<SO>Archives of Neurology</SO>
<YR>1998</YR>
<VL>55</VL>
<PG>981-4</PG>
<IDENTIFIERS MODIFIED="2011-04-07 11:06:54 +0100" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Cameron-2001" MODIFIED="2011-04-07 11:07:01 +0100" MODIFIED_BY="Ruth Brassington" NAME="Cameron 2001" TYPE="JOURNAL_ARTICLE">
<AU>Cameron NE, Eaton SE, Cotter MA, Tesfaye S</AU>
<TI>Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy</TI>
<SO>Diabetologia</SO>
<YR>2001</YR>
<VL>44</VL>
<NO>11</NO>
<PG>1973-88</PG>
<IDENTIFIERS MODIFIED="2011-04-07 11:07:01 +0100" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Cepeda-2006" MODIFIED="2011-04-07 10:52:44 +0100" MODIFIED_BY="Ruth Brassington" NAME="Cepeda 2006" TYPE="JOURNAL_ARTICLE">
<AU>Cepeda MS, Farrar JT</AU>
<TI>Economic evaluation of oral treatments for neuropathic pain</TI>
<SO>Journal of Pain</SO>
<YR>2006</YR>
<VL>7</VL>
<NO>2</NO>
<PG>119-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Challapalli-2005" MODIFIED="2016-04-12 00:01:47 +0100" MODIFIED_BY="Ruth Brassington" NAME="Challapalli 2005" TYPE="COCHRANE_REVIEW">
<AU>Challapalli V, Tremont-Lukats IW, McNicol ED, Lau J, Carr DB</AU>
<TI>Systemic administration of local anesthetic agents to relieve neuropathic pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2016-04-12 00:01:47 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2016-04-12 00:01:47 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD003345.pub2"/><IDENTIFIER MODIFIED="2016-02-15 10:17:42 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16235318"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chaparro-2012" MODIFIED="2017-04-03 15:59:07 +0100" MODIFIED_BY="Ruth Brassington" NAME="Chaparro 2012" TYPE="COCHRANE_REVIEW">
<AU>Chaparro LE, Wiffen PJ, Moore RA, Gilron I</AU>
<TI>Combination pharmacotherapy for the treatment of neuropathic pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2016-04-12 00:04:21 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2016-04-12 00:04:21 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD008943.pub2"/><IDENTIFIER TYPE="PUBMED" VALUE="22786518"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chia-1996" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Chia 1996" NOTES="&lt;p&gt;No issue no, available&lt;/p&gt;" NOTES_MODIFIED="2017-06-13 12:26:06 +0100" NOTES_MODIFIED_BY="Ruth Brassington" TYPE="JOURNAL_ARTICLE">
<AU>Chia L, Fernandez A, Lacroix C, Plante V, Said G</AU>
<TI>Contribution of nerve biopsy findings to the diagnosis of disabling neuropathy in the elderly. A retrospective review of 100 consecutive patients</TI>
<SO>Brain</SO>
<YR>1996</YR>
<VL>119</VL>
<PG>1091-8</PG>
<IDENTIFIERS MODIFIED="2011-04-07 11:07:12 +0100" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-2014" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Cohen 2014" NOTES="&lt;p&gt;No issue no. available&lt;/p&gt;" NOTES_MODIFIED="2017-06-13 12:26:06 +0100" NOTES_MODIFIED_BY="Ruth Brassington" TYPE="JOURNAL_ARTICLE">
<AU>Cohen SP, Mao J</AU>
<TI>Neuropathic pain: mechanisms and their clinical implications</TI>
<SO>BMJ</SO>
<YR>2014</YR>
<VL>348</VL>
<PG>f7656</PG>
<IDENTIFIERS MODIFIED="2016-02-15 09:55:29 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="24500412"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Deprez-2000" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Deprez 2000" TYPE="JOURNAL_ARTICLE">
<AU>Deprez M, De Groote CC, Gollogly L, Reznik M, Martin JJ</AU>
<TI>Clinical and neuropathological parameters affecting the diagnostic yield of nerve biopsy</TI>
<SO>Neuromuscular Disorders</SO>
<YR>2000</YR>
<VL>10</VL>
<NO>2</NO>
<PG>92-8</PG>
<IDENTIFIERS MODIFIED="2011-04-07 11:07:18 +0100" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Derry-2013" MODIFIED="2017-04-03 15:59:07 +0100" MODIFIED_BY="Ruth Brassington" NAME="Derry 2013" TYPE="COCHRANE_REVIEW">
<AU>Derry S, Rice Andrew S C, Cole P, Tan T, Moore RA</AU>
<TI>Topical capsaicin (high concentration) for chronic neuropathic pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2016-04-12 00:07:20 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2016-04-12 00:07:20 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD007393.pub3"/><IDENTIFIER MODIFIED="2016-02-15 10:33:13 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24217986"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Derry-2015" MODIFIED="2016-04-12 13:01:20 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Derry 2015" TYPE="COCHRANE_REVIEW">
<AU>Derry S, Phillips T, Moore RA, Wiffen PJ</AU>
<TI>Milnacipran for neuropathic pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2016-04-12 00:09:37 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2016-04-12 00:09:37 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD011789"/><IDENTIFIER TYPE="PUBMED" VALUE="26148202"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Duehmke-2006" MODIFIED="2016-04-12 00:05:51 +0100" MODIFIED_BY="Ruth Brassington" NAME="Duehmke 2006" TYPE="COCHRANE_REVIEW">
<AU>Duehmke RM, Hollingshead J, Cornblath DR</AU>
<TI>Tramadol for neuropathic pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2016-04-12 00:05:48 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2016-04-12 00:05:48 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD003726.pub3"/><IDENTIFIER MODIFIED="2016-02-15 11:38:41 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16856016"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dyck-1981" MODIFIED="2011-04-07 11:08:01 +0100" MODIFIED_BY="Ruth Brassington" NAME="Dyck 1981" TYPE="JOURNAL_ARTICLE">
<AU>Dyck PJ, Oviatt KF, Lambert EH</AU>
<TI>Intensive evaluation of referred unclassified neuropathies yields improved diagnosis</TI>
<SO>Annals of Neurology</SO>
<YR>1981</YR>
<VL>10</VL>
<PG>222-6</PG>
<IDENTIFIERS MODIFIED="2011-04-07 11:08:01 +0100" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Eliasson-2003" MODIFIED="2011-04-07 11:08:38 +0100" MODIFIED_BY="Ruth Brassington" NAME="Eliasson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Eliasson B</AU>
<TI>Cigarette smoking and diabetes</TI>
<SO>Progression in Cardiovascular Disease</SO>
<YR>2003</YR>
<VL>45</VL>
<NO>5</NO>
<PG>405-13</PG>
<IDENTIFIERS MODIFIED="2011-04-07 11:08:38 +0100" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Erdmann-2010" MODIFIED="2010-08-22 21:23:17 +0100" MODIFIED_BY="Alexander FJE Vrancken" NAME="Erdmann 2010" TYPE="JOURNAL_ARTICLE">
<AU>Erdmann PG, van Genderen FR, Teunissen LL, Notermans NC, Lindeman E, van Wijck AJ, et al</AU>
<TI>Pain in patients with chronic idiopathic axonal polyneuropathy</TI>
<SO>European Neurology</SO>
<YR>2010</YR>
<VL>64</VL>
<NO>1</NO>
<PG>58-64</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="20634621"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Farhad-2015" MODIFIED="2017-05-12 14:41:49 +0100" MODIFIED_BY="Ruth Brassington" NAME="Farhad 2015" NOTES="&lt;p&gt;Added pagination - was epub ahead of print&lt;/p&gt;" NOTES_MODIFIED="2017-05-12 14:41:49 +0100" NOTES_MODIFIED_BY="Ruth Brassington" TYPE="JOURNAL_ARTICLE">
<AU>Farhad K, Traub R, Ruzhansky KM, Brannagan TH 3rd</AU>
<TI>Causes of neuropathy in patients referred as "idiopathic neuropathy"</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>2016</YR>
<VL>53</VL>
<NO>6</NO>
<PG>858-61</PG>
<IDENTIFIERS MODIFIED="2016-02-15 10:38:14 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-02-15 10:38:14 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/mus.24969"/><IDENTIFIER TYPE="PUBMED" VALUE="26561790"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Finnerup-2015" MODIFIED="2016-04-12 00:10:05 +0100" MODIFIED_BY="Ruth Brassington" NAME="Finnerup 2015" TYPE="JOURNAL_ARTICLE">
<AU>Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al</AU>
<TI>Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis</TI>
<SO>Lancet Neurology</SO>
<YR>2015</YR>
<VL>14</VL>
<NO>2</NO>
<PG>162-73</PG>
<IDENTIFIERS MODIFIED="2016-02-15 09:55:29 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="25575710"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Forrest-1997" MODIFIED="2011-04-07 11:08:43 +0100" MODIFIED_BY="Ruth Brassington" NAME="Forrest 1997" TYPE="JOURNAL_ARTICLE">
<AU>Forrest KY, Maser RE, Pambianco G, Becker DJ, Orchard TJ</AU>
<TI>Hypertension as a risk factor for diabetic neuropathy: a prospective study</TI>
<SO>Diabetes</SO>
<YR>1997</YR>
<VL>46</VL>
<NO>4</NO>
<PG>665-70</PG>
<IDENTIFIERS MODIFIED="2011-04-07 11:08:43 +0100" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Fressinaud-2003" MODIFIED="2011-04-07 10:54:35 +0100" MODIFIED_BY="Ruth Brassington" NAME="Fressinaud 2003" TYPE="JOURNAL_ARTICLE">
<AU>Fressinaud C, Jean I, Dubas F</AU>
<TI>Selective decrease in axonal nerve growth factor and insulin-like growth factor I immunoreactivity in axonopathies of unknown etiology</TI>
<SO>Acta Neuropathologica (Berlin)</SO>
<YR>2003</YR>
<VL>105</VL>
<NO>5</NO>
<PG>477-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gabriel-2000" MODIFIED="2011-04-07 11:08:56 +0100" MODIFIED_BY="Ruth Brassington" NAME="Gabriel 2000" TYPE="JOURNAL_ARTICLE">
<AU>Gabriel CM, Howard R, Kinsella N, Lucas S, McColl I, Saldanha G, et al</AU>
<TI>Prospective study of the usefulness of sural nerve biopsy</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>2000</YR>
<VL>69</VL>
<PG>442-6</PG>
<IDENTIFIERS MODIFIED="2011-04-07 11:08:56 +0100" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Gilron-2014" MODIFIED="2016-04-12 00:10:14 +0100" MODIFIED_BY="Ruth Brassington" NAME="Gilron 2014" TYPE="JOURNAL_ARTICLE">
<AU>Gilron I, Dickenson AH</AU>
<TI>Emerging drugs for neuropathic pain</TI>
<SO>Expert Opinion on Emerging Drugs</SO>
<YR>2014</YR>
<VL>19</VL>
<NO>3</NO>
<PG>329-41</PG>
<IDENTIFIERS MODIFIED="2016-02-15 09:55:29 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="24793304"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Graham-2006a" MODIFIED="2011-04-07 10:55:13 +0100" MODIFIED_BY="Ruth Brassington" NAME="Graham 2006a" TYPE="JOURNAL_ARTICLE">
<AU>Graham RC, Hughes RAC</AU>
<TI>A modified peripheral neuropathy scale: the overall neuropathy limitations scale</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>2006</YR>
<VL>77</VL>
<NO>8</NO>
<PG>973-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Graham-2006b" MODIFIED="2011-04-07 10:55:23 +0100" MODIFIED_BY="Ruth Brassington" NAME="Graham 2006b" TYPE="JOURNAL_ARTICLE">
<AU>Graham RC, Hughes RAC</AU>
<TI>Clinimetric properties of a walking scale in peripheral neuropathy</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>2006</YR>
<VL>77</VL>
<NO>8</NO>
<PG>977-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grahmann-1991" MODIFIED="2011-04-07 11:13:09 +0100" MODIFIED_BY="Ruth Brassington" NAME="Grahmann 1991" TYPE="JOURNAL_ARTICLE">
<AU>Grahmann F, Winterholler M, Neundörfer B</AU>
<TI>Cryptogenetic polyneuropathies: an out-patient follow-up study</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1991</YR>
<VL>84</VL>
<PG>221-5</PG>
<IDENTIFIERS MODIFIED="2011-04-07 11:13:09 +0100" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Hernandez_x002d_Ojeda-2014" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Hernandez-Ojeda 2014" TYPE="JOURNAL_ARTICLE">
<AU>Hernandez-Ojeda J, Roman-Pintos LM, Rodriguez-Carrizalez AD, Troyo-Sanroman R, Cardona-Munoz EG, Alatorre-Carranza Mdel P, et al</AU>
<TI>Effect of rosuvastatin on diabetic polyneuropathy: a randomized, double-blind, placebo-controlled Phase IIa study</TI>
<SO>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</SO>
<YR>2014</YR>
<VL>7</VL>
<PG>401-7</PG>
<IDENTIFIERS MODIFIED="2016-02-12 15:39:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="25214797"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-04-12 13:02:16 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2004" MODIFIED="2011-04-07 10:57:49 +0100" MODIFIED_BY="Ruth Brassington" NAME="Hughes 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hughes RAC, Umapathi T, Gray IA, Gregson NA, Noori M, Pannala AS, Proteggente A, Swan AV</AU>
<TI>A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy</TI>
<SO>Brain</SO>
<YR>2004</YR>
<VL>127</VL>
<NO>Pt 8</NO>
<PG>1723-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-H_x00f6_ke-2005" MODIFIED="2017-03-17 09:55:26 +0000" MODIFIED_BY="Ruth Brassington" NAME="Höke 2005" TYPE="JOURNAL_ARTICLE">
<AU>Höke A, Keswani SC</AU>
<TI>Neuroprotection in the PNS: erythropoietin and immunophilin ligands</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>2005</YR>
<VL>1053</VL>
<PG>491-501</PG>
<IDENTIFIERS MODIFIED="2016-02-16 11:28:50 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-02-16 11:28:50 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16179557"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jann-1998" MODIFIED="2008-05-05 17:31:31 +0100" MODIFIED_BY="[Empty name]" NAME="Jann 1998" TYPE="JOURNAL_ARTICLE">
<AU>Jann S, Gatti A, Crespi S, Rolo J, Beretta S</AU>
<TI>Peripheral neuropathy in chronic respiratory insufficiency</TI>
<SO>Journal of the Peripheral Nervous System</SO>
<YR>1998</YR>
<VL>3</VL>
<NO>1</NO>
<PG>69-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jann-2001" MODIFIED="2011-04-07 10:57:58 +0100" MODIFIED_BY="Ruth Brassington" NAME="Jann 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jann S, Beretta S, Bramerio M, Defanti CA</AU>
<TI>Prospective follow-up study of chronic polyneuropathy of undetermined cause</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>9</NO>
<PG>1197-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kleyweg-1991" MODIFIED="2011-04-07 11:09:59 +0100" MODIFIED_BY="Ruth Brassington" NAME="Kleyweg 1991" TYPE="JOURNAL_ARTICLE">
<AU>Kleyweg RP, van der Meche FG, Schmitz PI</AU>
<TI>Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>1991</YR>
<VL>14</VL>
<PG>1103-9</PG>
<IDENTIFIERS MODIFIED="2011-04-07 11:09:59 +0100" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Lehmann-2010" MODIFIED="2017-03-17 09:57:26 +0000" MODIFIED_BY="Ruth Brassington" NAME="Lehmann 2010" TYPE="JOURNAL_ARTICLE">
<AU>Lehmann HC, Höke A</AU>
<TI>Schwann cells as a therapeutic target for peripheral neuropathies</TI>
<SO>CNS &amp; Neurological Disorders Drug Targets</SO>
<YR>2010</YR>
<VL>9</VL>
<NO>6</NO>
<PG>801-6</PG>
<IDENTIFIERS MODIFIED="2016-02-16 12:45:14 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-02-16 12:45:14 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20874704"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leinninger-2004" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Leinninger 2004" TYPE="JOURNAL_ARTICLE">
<AU>Leinninger GM, Vincent AM, Feldman EL</AU>
<TI>The role of growth factors in diabetic peripheral neuropathy</TI>
<SO>Journal of the Peripheral Nervous System</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>1</NO>
<PG>26-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindh-2005" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Lindh 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lindh J, Tondel M, Österberg A, Vrethem M</AU>
<TI>Cryptogenic polyneuropathy: clinical and neurophysiological findings</TI>
<SO>Journal of the Peripheral Nervous System</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>1</NO>
<PG>31-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindh-2011a" MODIFIED="2017-04-03 15:59:07 +0100" MODIFIED_BY="Ruth Brassington" NAME="Lindh 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Lindh J, Tondel M, Persson B, Vrethem M</AU>
<TI>Health-related quality of life in patients with cryptogenic polyneuropathy compared with the general population</TI>
<SO>Disability and Rehabilitation</SO>
<YR>2011</YR>
<VL>33</VL>
<NO>7</NO>
<PG>617-23</PG>
<IDENTIFIERS MODIFIED="2016-02-12 15:39:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="20690857"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lindh-2011b" MODIFIED="2017-04-03 15:59:07 +0100" MODIFIED_BY="Ruth Brassington" NAME="Lindh 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Lindh J, Soderkvist P, Fredrikson M, Hosseininia S, Tondel M, Persson B, et al</AU>
<TI>Polymorphisms of GSTT1, GSTM1, and EPHX genotypes in patients with cryptogenic polyneuropathy: a case-control study</TI>
<SO>Brain and Behavior</SO>
<YR>2011</YR>
<VL>1</VL>
<NO>2</NO>
<PG>135-41</PG>
<IDENTIFIERS MODIFIED="2016-02-12 15:39:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="22399093"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Logigian-1994" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Logigian 1994" TYPE="JOURNAL_ARTICLE">
<AU>Logigian EL, Kelly JJ, Jr, Adelman LS</AU>
<TI>Nerve conduction and biopsy correlation in over 100 consecutive patients with suspected polyneuropathy</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>1994</YR>
<VL>17</VL>
<NO>9</NO>
<PG>1010-20</PG>
<IDENTIFIERS MODIFIED="2011-04-07 11:10:07 +0100" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Malik-2000" MODIFIED="2008-05-05 17:31:32 +0100" MODIFIED_BY="[Empty name]" NAME="Malik 2000" TYPE="JOURNAL_ARTICLE">
<AU>Malik RA</AU>
<TI>Can diabetic neuropathy be prevented by angiotensin-converting enzyme inhibitors?</TI>
<SO>Annals of Medicine</SO>
<YR>2000</YR>
<VL>32</VL>
<NO>1</NO>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Markman-2006" MODIFIED="2008-05-05 17:31:32 +0100" MODIFIED_BY="[Empty name]" NAME="Markman 2006" TYPE="JOURNAL_ARTICLE">
<AU>Markman JD, Dworkin RH</AU>
<TI>Ion channel targets and treatment efficacy in neuropathic pain</TI>
<SO>Journal of Pain</SO>
<YR>2006</YR>
<VL>7</VL>
<NO>15 Supplement 1</NO>
<PG>S38-S47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McLeod-1984" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="McLeod 1984" TYPE="JOURNAL_ARTICLE">
<AU>McLeod JG, Tuck RR, Pollard JD, Cameron J, Walsh JC</AU>
<TI>Chronic polyneuropathy of undetermined cause</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1984</YR>
<VL>47</VL>
<NO>5</NO>
<PG>530-5</PG>
<IDENTIFIERS MODIFIED="2017-05-30 15:23:54 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2017-05-30 15:23:54 +0100" MODIFIED_BY="Ruth Brassington" TYPE="PUBMED" VALUE="1027832"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McNicol-2013" MODIFIED="2017-04-03 15:59:07 +0100" MODIFIED_BY="Ruth Brassington" NAME="McNicol 2013" TYPE="COCHRANE_REVIEW">
<AU>McNicol ED, Midbari A, Eisenberg E</AU>
<TI>Opioids for neuropathic pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2016-04-12 12:34:59 +0100" MODIFIED_BY="Ruth  Brassington"><IDENTIFIER MODIFIED="2016-04-12 12:34:59 +0100" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD006146.pub2"/><IDENTIFIER TYPE="PUBMED" VALUE="23986501"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Merkies-2006" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Merkies 2006" TYPE="JOURNAL_ARTICLE">
<AU>Merkies ISJ, Lauria G</AU>
<TI>131st ENMC International workshop: selection of outcome measures for peripheral neuropathy clinical trials, 10-12 December, Naarden, The Netherlands</TI>
<SO>Neuromuscular Disorders</SO>
<YR>2006</YR>
<VL>16</VL>
<PG>149-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miller-2012" MODIFIED="2017-04-03 15:59:07 +0100" MODIFIED_BY="Ruth Brassington" NAME="Miller 2012" TYPE="COCHRANE_REVIEW">
<AU>Miller RG, Mitchell JD, Moore DH</AU>
<TI>Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2016-04-12 00:12:57 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2016-04-12 00:12:57 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD001447.pub3"/><IDENTIFIER MODIFIED="2016-02-15 11:42:22 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="22419278"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moore-2015a" MODIFIED="2017-03-17 09:57:46 +0000" MODIFIED_BY="Ruth Brassington" NAME="Moore 2015a" TYPE="COCHRANE_PROTOCOL">
<AU>Moore RA, Kalso EA, Wiffen PJ, Derry S, Tölle TR, Finnerup NB, et al</AU>
<TI>Antidepressant drugs for neuropathic pain - an overview of Cochrane reviews</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2016-02-15 13:48:14 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-02-15 13:48:14 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD011606"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moore-2015b" MODIFIED="2017-03-17 09:58:06 +0000" MODIFIED_BY="Ruth Brassington" NAME="Moore 2015b" TYPE="COCHRANE_REVIEW">
<AU>Moore RA, Wiffen PJ, Derry S, Lunn MP</AU>
<TI>Zonisamide for neuropathic pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2016-04-12 00:14:30 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2016-04-12 00:14:30 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD011241.pub2"/><IDENTIFIER TYPE="PUBMED" VALUE="25879104"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moore-2015c" MODIFIED="2017-03-17 09:57:55 +0000" MODIFIED_BY="Ruth Brassington" NAME="Moore 2015c" TYPE="COCHRANE_REVIEW">
<AU>Moore RA, Chi CC, Wiffen PJ, Derry S, Rice AS</AU>
<TI>Oral nonsteroidal anti-inflammatory drugs for neuropathic pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>10</NO>
<PG>CD010902</PG>
<IDENTIFIERS MODIFIED="2016-04-12 00:16:05 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2016-04-12 00:16:05 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD010902.pub2"/><IDENTIFIER TYPE="PUBMED" VALUE="26436601"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-M_x00fc_ller-2005" MODIFIED="2011-04-07 10:59:23 +0100" MODIFIED_BY="Ruth Brassington" NAME="Müller 2005" TYPE="JOURNAL_ARTICLE">
<AU>Müller BK, Mack H, Teusch N</AU>
<TI>Rho kinase, a promising drug target for neurological disorders</TI>
<SO>Nature Reviews Drug Discovery</SO>
<YR>2005</YR>
<VL>4</VL>
<NO>5</NO>
<PG>387-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nebuchennykh-2008" MODIFIED="2011-04-07 10:59:04 +0100" MODIFIED_BY="Ruth Brassington" NAME="Nebuchennykh 2008" TYPE="JOURNAL_ARTICLE">
<AU>Nebuchennykh M, Loseth S, Jorde R, Mellgren SI</AU>
<TI>Idiopathic polyneuropathy and impaired glucose metabolism in a Norwegian patient series</TI>
<SO>European Journal of Neurology</SO>
<YR>2008</YR>
<VL>15</VL>
<NO>8</NO>
<PG>810-6</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="18549398"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Notermans-1993" MODIFIED="2011-04-07 11:12:00 +0100" MODIFIED_BY="Ruth Brassington" NAME="Notermans 1993" TYPE="JOURNAL_ARTICLE">
<AU>Notermans NC, Wokke JHJ, Franssen H, Van der Graaf Y, Vermeulen M, Van den Berg LH, et al</AU>
<TI>Chronic idiopathic polyneuropathy presenting in middle or old age: a clinical and electrophysiological study of 75 patients</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1993</YR>
<VL>56</VL>
<PG>1066-71</PG>
<IDENTIFIERS MODIFIED="2011-04-07 11:12:00 +0100" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Notermans-1994" MODIFIED="2011-04-07 11:11:52 +0100" MODIFIED_BY="Ruth Brassington" NAME="Notermans 1994" TYPE="JOURNAL_ARTICLE">
<AU>Notermans NC, Wokke JHJ, Van der Graaf Y, Franssen H, van Dijk GW, Jennekens FG</AU>
<TI>Chronic idiopathic axonal polyneuropathy: a five year follow up</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1994</YR>
<VL>57</VL>
<PG>1525-7</PG>
<IDENTIFIERS MODIFIED="2011-04-07 11:11:52 +0100" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Persson-2013" MODIFIED="2016-04-12 13:02:29 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Persson 2013" TYPE="JOURNAL_ARTICLE">
<AU>Persson B, Vrethem M, Murgia N, Lindh J, Hallsten AL, Fredrikson M, et al</AU>
<TI>Urinary 2,5-hexanedione excretion in cryptogenic polyneuropathy compared to the general Swedish population</TI>
<SO>Journal of Occupational Medicine and Toxicology</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>1</NO>
<PG>21</PG>
<IDENTIFIERS MODIFIED="2016-02-12 15:39:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="23898939"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Poza-1997" MODIFIED="2011-04-07 11:00:21 +0100" MODIFIED_BY="Ruth Brassington" NAME="Poza 1997" TYPE="JOURNAL_ARTICLE">
<AU>Poza JJ, Martí-Massó JF</AU>
<TI>Peripheral neuropathy associated with chronic obstructive pulmonary disease</TI>
<TO>Neuropatía periférica asociada a enfermedad pulmonar obstructiva crónica</TO>
<SO>Neurología</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>9</NO>
<PG>389-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pradat-2003" MODIFIED="2017-05-30 15:24:55 +0100" MODIFIED_BY="Ruth Brassington" NAME="Pradat 2003" TYPE="JOURNAL_ARTICLE">
<AU>Pradat PF</AU>
<TI>Treatment of peripheral neuropathies with neurotrophic factors: animal models and clinical trials</TI>
<TO>Traitement des neuropathies périphériques par les facteurs neurotrophiques: des models animaux et essais thérapeutiques</TO>
<SO>Revue Neurologique</SO>
<YR>2003</YR>
<VL>159</VL>
<NO>2</NO>
<PG>147-61</PG>
<IDENTIFIERS MODIFIED="2017-05-30 15:24:55 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2017-05-30 15:24:55 +0100" MODIFIED_BY="Ruth Brassington" TYPE="PUBMED" VALUE="12660566 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rajabally-2011a" MODIFIED="2017-05-12 14:44:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Rajabally 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Rajabally YA</AU>
<TI>Neuropathy and impaired glucose tolerance: an updated review of the evidence</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>2011</YR>
<VL>124</VL>
<NO>1</NO>
<PG>1-8</PG>
<IDENTIFIERS MODIFIED="2016-02-12 15:39:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="20868430"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rajabally-2011b" MODIFIED="2017-03-17 09:58:17 +0000" MODIFIED_BY="Ruth Brassington" NAME="Rajabally 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Rajabally YA, Shah RS</AU>
<TI>Dyslipidaemia in chronic acquired distal axonal polyneuropathy</TI>
<SO>Journal of Neurology</SO>
<YR>2011</YR>
<VL>258</VL>
<NO>8</NO>
<PG>1431-6</PG>
<IDENTIFIERS MODIFIED="2016-02-12 15:39:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21331599"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rankin-1957" MODIFIED="2011-04-07 11:00:41 +0100" MODIFIED_BY="Ruth Brassington" NAME="Rankin 1957" TYPE="JOURNAL_ARTICLE">
<AU>Rankin J</AU>
<TI>Cerebral vascular accidents in patients over the age of 60: II. Prognosis</TI>
<SO>Scottish Medical Journal</SO>
<YR>1957</YR>
<VL>2</VL>
<PG>200-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2016-04-12 13:02:41 +0100" MODIFIED_BY="Ruth  Brassington" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan). Version 5.3.5</TI>
<YR>2014</YR>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roglio-2008" MODIFIED="2017-03-17 09:58:27 +0000" MODIFIED_BY="Ruth Brassington" NAME="Roglio 2008" TYPE="JOURNAL_ARTICLE">
<AU>Roglio I, Giatti S, Pesaresi M, Bianchi R, Cavaletti G, Lauria G, et al</AU>
<TI>Neuroactive steroids and peripheral neuropathy</TI>
<SO>Brain Research Reviews</SO>
<YR>2008</YR>
<VL>57</VL>
<NO>2</NO>
<PG>460-9</PG>
<IDENTIFIERS MODIFIED="2016-02-16 12:58:01 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-02-16 12:58:01 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17543391"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rosenberg-2004" MODIFIED="2016-04-12 12:57:40 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Rosenberg 2004" TYPE="JOURNAL_ARTICLE">
<AU>Rosenberg NR, Vermeulen M</AU>
<TI>Chronic idiopathic axonal polyneuropathy revisited</TI>
<SO>Journal of Neurology</SO>
<YR>2004</YR>
<VL>251</VL>
<NO>9</NO>
<PG>1128-32</PG>
<IDENTIFIERS MODIFIED="2016-02-12 15:39:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="15372258"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sah-2003" MODIFIED="2017-05-30 15:25:33 +0100" MODIFIED_BY="Ruth Brassington" NAME="Sah 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sah DW, Ossipo MH, Porreca F</AU>
<TI>Neurotrophic factors as novel therapeutics for neuropathic pain</TI>
<SO>Nature Reviews. Drug Discovery</SO>
<YR>2003</YR>
<VL>2</VL>
<NO>6</NO>
<PG>460-72</PG>
<IDENTIFIERS MODIFIED="2017-05-30 15:25:33 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2017-05-30 15:25:33 +0100" MODIFIED_BY="Ruth Brassington" TYPE="PUBMED" VALUE="12776221"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Saperstein-2003" MODIFIED="2008-05-05 17:31:31 +0100" MODIFIED_BY="[Empty name]" NAME="Saperstein 2003" TYPE="JOURNAL_ARTICLE">
<AU>Saperstein DS, Wolfe GI, Gronseth GS, Nations SP, Herbelin LL, Bryan WW, Barohn RJ</AU>
<TI>Challenges in the identification of cobalamin-deficiency polyneuropathy</TI>
<SO>Archives of Neurology</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>9</NO>
<PG>1296-1301</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Singer-2012" MODIFIED="2017-03-17 10:03:58 +0000" MODIFIED_BY="Ruth Brassington" NAME="Singer 2012" TYPE="JOURNAL_ARTICLE">
<AU>Singer MA, Vernino SA, Wolfe GI</AU>
<TI>Idiopathic neuropathy: new paradigms, new promise</TI>
<SO>Journal of the Peripheral Nervous System</SO>
<YR>2012</YR>
<VL>17</VL>
<NO>Suppl 2</NO>
<PG>43-9</PG>
<IDENTIFIERS MODIFIED="2016-02-12 15:39:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="22548623"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Smith-2006" MODIFIED="2011-04-07 11:00:53 +0100" MODIFIED_BY="Ruth Brassington" NAME="Smith 2006" TYPE="JOURNAL_ARTICLE">
<AU>Smith AG, Russell J, Feldman EL, Goldstein J, Peltier A, Smith S, et al</AU>
<TI>Lifestyle intervention for pre-diabetic neuropathy</TI>
<SO>Diabetes Care</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>6</NO>
<PG>1294-9</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="16732011"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Smith-2008" MODIFIED="2016-02-15 15:41:43 +0000" MODIFIED_BY="[Empty name]" NAME="Smith 2008" TYPE="JOURNAL_ARTICLE">
<AU>Smith AG, Rose K, Singleton JR</AU>
<TI>Idiopathic neuropathy patients are at high risk for metabolic syndrome</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2008</YR>
<VL>273</VL>
<NO>1-2</NO>
<PG>25-8</PG>
<IDENTIFIERS><IDENTIFIER TYPE="PUBMED" VALUE="18606421"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Smith-2013" MODIFIED="2016-04-12 12:58:13 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Smith 2013" TYPE="JOURNAL_ARTICLE">
<AU>Smith BH, Lee J, Price C, Baranowski AP</AU>
<TI>Neuropathic pain: a pathway for care developed by the British Pain Society</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2013</YR>
<VL>111</VL>
<NO>1</NO>
<PG>73-9</PG>
<IDENTIFIERS MODIFIED="2016-02-15 09:55:29 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="23794648"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Streckmann-2014" MODIFIED="2017-03-17 10:04:08 +0000" MODIFIED_BY="Ruth Brassington" NAME="Streckmann 2014" TYPE="JOURNAL_ARTICLE">
<AU>Streckmann F, Zopf EM, Lehmann HC, May K, Rizza J, Zimmer P, et al</AU>
<TI>Exercise intervention studies in patients with peripheral neuropathy: a systematic review (Provisional abstract)</TI>
<SO>Sports Medicine</SO>
<YR>2014</YR>
<VL>44</VL>
<NO>9</NO>
<PG>1289-304</PG>
<IDENTIFIERS MODIFIED="2016-02-16 17:25:44 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-02-16 17:25:44 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24927670"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Teunissen-2000a" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Teunissen 2000a" TYPE="JOURNAL_ARTICLE">
<AU>Teunissen LL, Eurelings M, Notermans NC, Hop JW, van Gijn J</AU>
<TI>Quality of life in patients with axonal polyneuropathy</TI>
<SO>Journal of Neurology</SO>
<YR>2000</YR>
<VL>247</VL>
<NO>3</NO>
<PG>195-9</PG>
<IDENTIFIERS MODIFIED="2011-04-07 12:25:22 +0100" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Teunissen-2000b" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Teunissen 2000b" TYPE="JOURNAL_ARTICLE">
<AU>Teunissen LL, Notermans NC, Wokke JHJ</AU>
<TI>Relationship between ischemia and neuropathy</TI>
<SO>European Neurology</SO>
<YR>2000</YR>
<VL>44</VL>
<NO>1</NO>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Teunissen-2000c" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Teunissen 2000c" TYPE="JOURNAL_ARTICLE">
<AU>Teunissen LL, Notermans NC, Jansen GH, Banga JD, Veldman H, Wokke JHJ</AU>
<TI>Thickness of endoneurial vessel basal lamina area in chronic idiopathic axonal polyneuropathy</TI>
<SO>Acta Neuropathologica (Berlin)</SO>
<YR>2000</YR>
<VL>100</VL>
<NO>4</NO>
<PG>445-50</PG>
<IDENTIFIERS MODIFIED="2011-04-07 11:11:17 +0100" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Teunissen-2002" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Teunissen 2002" TYPE="JOURNAL_ARTICLE">
<AU>Teunissen LL, Franssen H, Wokke JHJ, Van der Graaf Y, Linssen WHJP, Banga JD, et al</AU>
<TI>Is cardiovascular disease a risk factor in the development of axonal polyneuropathy?</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>2002</YR>
<VL>72</VL>
<NO>5</NO>
<PG>590-5</PG>
<IDENTIFIERS MODIFIED="2011-04-07 11:11:10 +0100" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-2015" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Thompson 2015" NOTES="&lt;p&gt;Added page numbers and volume No issue number given&lt;/p&gt;" NOTES_MODIFIED="2017-06-13 12:26:06 +0100" NOTES_MODIFIED_BY="Ruth Brassington" TYPE="JOURNAL_ARTICLE">
<AU>Thompson DF, Brooks KG</AU>
<TI>Systematic review of topical amitriptyline for the treatment of neuropathic pain</TI>
<SO>Journal of Clinical Pharmacy and Therapeutics</SO>
<YR>2015</YR>
<VL>40</VL>
<PG>496-503</PG>
<IDENTIFIERS MODIFIED="2016-02-15 12:08:38 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-02-15 12:08:38 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1111/jcpt.12297"/><IDENTIFIER MODIFIED="2016-02-15 12:08:31 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="26059975"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tierney-2013" MODIFIED="2016-04-12 13:02:51 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Tierney 2013" TYPE="JOURNAL_ARTICLE">
<AU>Tierney EF, Thurman DJ, Beckles GL, Cadwell BL</AU>
<TI>Association of statin use with peripheral neuropathy in the U.S. population 40 years of age or older</TI>
<SO>Journal of Diabetes</SO>
<YR>2013</YR>
<VL>5</VL>
<NO>2</NO>
<PG>207-15</PG>
<IDENTIFIERS MODIFIED="2016-02-12 15:39:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="23121724"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tondel-2006" MODIFIED="2016-02-12 15:39:55 +0000" MODIFIED_BY="[Empty name]" NAME="Tondel 2006" TYPE="JOURNAL_ARTICLE">
<AU>Tondel M, Lindh J, Jonsson P, Vrethem M, Persson B</AU>
<TI>Occupational determinants of cryptogenic polyneuropathy</TI>
<SO>Neuroepidemiology</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>4</NO>
<PG>187-94</PG>
<IDENTIFIERS MODIFIED="2016-02-12 15:39:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="16569935"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-van-Swieten-1988" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="van Swieten 1988" TYPE="JOURNAL_ARTICLE">
<AU>van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J</AU>
<TI>Interobserver agreement for the assessment of handicap in stroke patients</TI>
<SO>Stroke</SO>
<YR>1988</YR>
<VL>19</VL>
<NO>5</NO>
<PG>604-7</PG>
<IDENTIFIERS MODIFIED="2011-04-07 11:11:01 +0100" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Verghese-2001" MODIFIED="2016-04-12 13:02:58 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Verghese 2001" TYPE="JOURNAL_ARTICLE">
<AU>Verghese J, Bieri PL, Gellido C, Schaumburg HH, Herskovitz S</AU>
<TI>Peripheral neuropathy in young-old and old-old patients</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>11</NO>
<PG>1476-81</PG>
<IDENTIFIERS MODIFIED="2016-02-12 15:39:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="11745949"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vilming-1987" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Vilming 1987" TYPE="JOURNAL_ARTICLE">
<AU>Vilming ST, Stave R</AU>
<TI>Idiopathic polyneuropathy. A prospective study including gastrointestinal investigation</TI>
<SO>Journal of Oslo City Hospital</SO>
<YR>1987</YR>
<VL>37</VL>
<NO>11-2</NO>
<PG>129-34</PG>
<IDENTIFIERS MODIFIED="2011-04-07 12:25:35 +0100" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Visser-2013" MODIFIED="2017-03-17 10:04:23 +0000" MODIFIED_BY="Ruth Brassington" NAME="Visser 2013" TYPE="JOURNAL_ARTICLE">
<AU>Visser NA, Vrancken AFJE, van der Schouw YT, van den Berg LH, Notermans NC</AU>
<TI>Chronic idiopathic axonal polyneuropathy is associated with the metabolic syndrome</TI>
<SO>Diabetes Care</SO>
<YR>2013</YR>
<VL>36</VL>
<NO>4</NO>
<PG>817-22</PG>
<IDENTIFIERS MODIFIED="2016-02-12 09:30:31 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-02-12 09:30:31 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="23204246"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Visser-2014" MODIFIED="2017-03-17 10:04:42 +0000" MODIFIED_BY="Ruth Brassington" NAME="Visser 2014" TYPE="JOURNAL_ARTICLE">
<AU>Visser NA, Notermans NC, Degen LA, de Kruijk JR, van den Berg LH, Vrancken AFJE</AU>
<TI>Chronic idiopathic axonal polyneuropathy and vitamin B6: a controlled population-based study</TI>
<SO>Journal of the Peripheral Nervous System</SO>
<YR>2014</YR>
<VL>19</VL>
<NO>2</NO>
<PG>136-44</PG>
<IDENTIFIERS MODIFIED="2016-02-12 09:32:24 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-02-12 09:32:24 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24813907"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Visser-2015" MODIFIED="2017-03-17 10:04:50 +0000" MODIFIED_BY="Ruth Brassington" NAME="Visser 2015" TYPE="JOURNAL_ARTICLE">
<AU>Visser NA, Notermans NC, Linssen RS, van den Berg LH, Vrancken AFJE</AU>
<TI>Incidence of polyneuropathy in Utrecht, the Netherlands</TI>
<SO>Neurology</SO>
<YR>2015</YR>
<VL>84</VL>
<NO>3</NO>
<PG>259-64</PG>
<IDENTIFIERS MODIFIED="2016-02-10 15:31:46 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-02-10 15:31:26 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="25503982"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vrancken-2002a" MODIFIED="2017-05-30 12:57:12 +0100" MODIFIED_BY="[Empty name]" NAME="Vrancken 2002a" TYPE="JOURNAL_ARTICLE">
<AU>Vrancken AFJE, Franssen H, Wokke JHJ, Teunissen LL, Notermans NC</AU>
<TI>Chronic idiopathic axonal polyneuropathy and successful aging of the peripheral nervous system in elderly people</TI>
<SO>Archives of Neurology</SO>
<YR>2002</YR>
<VL>59</VL>
<NO>4</NO>
<PG>533-40</PG>
<IDENTIFIERS MODIFIED="2011-04-07 11:10:56 +0100" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Vrancken-2004a" MODIFIED="2017-06-13 12:26:06 +0100" MODIFIED_BY="Ruth Brassington" NAME="Vrancken 2004a" TYPE="JOURNAL_ARTICLE">
<AU>Vrancken AFJE, Notermans NC, Jansen GH, Wokke JHJ, Said G</AU>
<TI>Progressive idiopathic axonal neuropathy: a comparative clinical and histopathological study with vasculitic neuropathy</TI>
<SO>Journal of Neurology</SO>
<YR>2004</YR>
<VL>251</VL>
<NO>3</NO>
<PG>269-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-White-2004" MODIFIED="2016-04-12 12:32:47 +0100" MODIFIED_BY="Ruth  Brassington" NAME="White 2004" TYPE="COCHRANE_REVIEW">
<AU>White CM, Pritchard J, Turner-Stokes L</AU>
<TI>Exercise for people with peripheral neuropathy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2016-04-12 12:32:47 +0100" MODIFIED_BY="Ruth  Brassington"><IDENTIFIER MODIFIED="2016-04-12 12:32:47 +0100" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD003904.pub2"/><IDENTIFIER MODIFIED="2016-02-15 12:12:46 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15495069"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-White-2014" MODIFIED="2016-04-12 13:00:08 +0100" MODIFIED_BY="Ruth  Brassington" NAME="White 2014" TYPE="COCHRANE_REVIEW">
<AU>White CM, van Doorn PA, Garssen MPJ, Stockley RC</AU>
<TI>Interventions for fatigue in peripheral neuropathy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2016-04-12 00:18:52 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2016-04-12 00:18:52 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD008146.pub2"/><IDENTIFIER MODIFIED="2016-02-15 08:39:03 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="25519471"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wiffen-2013" MODIFIED="2017-04-03 15:59:07 +0100" MODIFIED_BY="Ruth Brassington" NAME="Wiffen 2013" TYPE="COCHRANE_REVIEW">
<AU>Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice ASC, et al</AU>
<TI>Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2016-04-12 00:20:23 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2016-04-12 00:20:23 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD010567.pub2"/><IDENTIFIER MODIFIED="2016-02-15 12:57:59 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="24217986"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wiffen-2014" MODIFIED="2016-04-12 13:00:40 +0100" MODIFIED_BY="Ruth  Brassington" NAME="Wiffen 2014" TYPE="COCHRANE_REVIEW">
<AU>Wiffen PJ, Derry S, Moore RA, Lunn MP</AU>
<TI>Levetiracetam for neuropathic pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2016-04-12 00:21:50 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2016-04-12 00:21:50 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD010943.pub2"/><IDENTIFIER TYPE="PUBMED" VALUE="25000215"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wiffen-2015" MODIFIED="2017-04-03 15:59:07 +0100" MODIFIED_BY="Ruth Brassington" NAME="Wiffen 2015" TYPE="COCHRANE_REVIEW">
<AU>Wiffen PJ, Derry S, Moore RA, Stannard C, Aldington D, Cole P, et al</AU>
<TI>Buprenorphine for neuropathic pain in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2016-04-12 12:33:45 +0100" MODIFIED_BY="Ruth  Brassington"><IDENTIFIER MODIFIED="2016-04-12 12:33:45 +0100" MODIFIED_BY="Ruth  Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD011603.pub2"/><IDENTIFIER TYPE="PUBMED" VALUE="26421677"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wolfe-1999" MODIFIED="2011-04-07 11:10:28 +0100" MODIFIED_BY="Ruth Brassington" NAME="Wolfe 1999" TYPE="JOURNAL_ARTICLE">
<AU>Wolfe GI, Baker NS, Amato AA, Jackson CE, Nations SP, Saperstein DS, et al</AU>
<TI>Chronic cryptogenic sensory polyneuropathy: clinical and laboratory characteristics</TI>
<SO>Archives of Neurology</SO>
<YR>1999</YR>
<VL>56</VL>
<PG>540-7</PG>
<IDENTIFIERS MODIFIED="2011-04-07 11:10:28 +0100" MODIFIED_BY="Ruth Brassington"/>
</REFERENCE>
<REFERENCE ID="REF-Wrzosek-2015" MODIFIED="2017-04-03 15:59:07 +0100" MODIFIED_BY="Ruth Brassington" NAME="Wrzosek 2015" TYPE="COCHRANE_REVIEW">
<AU>Wrzosek A, Woron J, Dobrogowski J, Jakowicka-Wordliczek J, Wordliczek J</AU>
<TI>Topical clonidine for neuropathic pain</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2015</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2016-04-12 00:23:06 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2016-04-12 00:23:06 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD010967.pub2"/><IDENTIFIER MODIFIED="2016-02-15 12:59:33 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="26329307"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ziegler-2011" MODIFIED="2017-03-17 09:54:40 +0000" MODIFIED_BY="Ruth Brassington" NAME="Ziegler 2011" TYPE="JOURNAL_ARTICLE">
<AU>Ziegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, et al</AU>
<TI>Efficacy and safety of antioxidant treatment with &#945;-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial</TI>
<SO>Diabetes Care</SO>
<YR>2011</YR>
<VL>34</VL>
<NO>9</NO>
<PG>2054-60</PG>
<IDENTIFIERS MODIFIED="2016-02-15 15:26:47 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-02-15 15:26:47 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21775755"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zochodne-2005" MODIFIED="2011-04-07 11:02:41 +0100" MODIFIED_BY="Ruth Brassington" NAME="Zochodne 2005" TYPE="JOURNAL_ARTICLE">
<AU>Zochodne DW, Levy D</AU>
<TI>Nitric oxide in damage, disease and repair of the peripheral nervous system</TI>
<SO>Cellular &amp; Molecular Biology</SO>
<YR>2005</YR>
<VL>51</VL>
<NO>3</NO>
<PG>255-67</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-05-12 12:31:08 +0100" MODIFIED_BY="Ruth Brassington">
<REFERENCE ID="REF-Vrancken-2002b" MODIFIED="2017-05-12 12:31:00 +0100" MODIFIED_BY="Ruth Brassington" NAME="Vrancken 2002b" TYPE="COCHRANE_PROTOCOL">
<AU>Vrancken A, Van Schaik I, Hughes R, Notermans N</AU>
<TI>Drug therapy for chronic idiopathic axonal polyneuropathy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2017-05-10 16:32:43 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2017-05-10 16:32:43 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD003456"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vrancken-2004b" MODIFIED="2017-05-12 12:31:08 +0100" MODIFIED_BY="Ruth Brassington" NAME="Vrancken 2004b" TYPE="COCHRANE_REVIEW">
<AU>Vrancken AFJE , Van Schaik IN, Hughes RAC, Notermans NC</AU>
<TI>Drug therapy for chronic idiopathic axonal polyneuropathy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2017-05-10 16:34:51 +0100" MODIFIED_BY="Ruth Brassington"><IDENTIFIER MODIFIED="2017-05-10 16:34:51 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD003456.pub2"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2010-11-16 22:37:43 +0000" MODIFIED_BY="Alexander FJE Vrancken"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-06-13 12:22:12 +0100" MODIFIED_BY="Ruth Brassington">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-07-06 14:57:59 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-06-13 12:22:12 +0100" MODIFIED_BY="Ruth Brassington" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:01 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Attal-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:01 +0100" MODIFIED_BY="Ruth Brassington">
<P>Neuropathic pain of various origins, including idiopathic sensory neuropathy<BR/>No separate analyses for idiopathic sensory neuropathy<BR/>Idiopathic sensory neuropathy not well defined (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:01 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Bradley-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:01 +0100" MODIFIED_BY="Ruth Brassington">
<P>No separate analyses for idiopathic polyneuropathy<BR/>Idiopathic polyneuropathy not well defined (i.e. not defined as CIAP)<BR/>No useful outcome measures</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:02 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-De-Grandis-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:02 +0100" MODIFIED_BY="Ruth Brassington">
<P>No separate analyses for idiopathic neuropathy<BR/>Idiopathic neuropathy not well defined (i.e. not defined as CIAP)<BR/>No useful outcome measures</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:02 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Demant-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:02 +0100" MODIFIED_BY="Ruth Brassington">
<P>Peripheral neuropathic pain of various origins, including idiopathic polyneuropathy<BR/>No separate analyses for idiopathic polyneuropathy<BR/>Idiopathic polyneuropathy not well defined (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:02 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Frank-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:02 +0100" MODIFIED_BY="Ruth Brassington">
<P>Neuropathic pain of various origins, including unspecified neuropathy (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:02 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Galer-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:02 +0100" MODIFIED_BY="Ruth Brassington">
<P>Diabetic and non-diabetic polyneuropathy of various unspecified origins</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:03 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Gilron-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:03 +0100" MODIFIED_BY="Ruth Brassington">
<P>Hereditary/idiopathic peripheral neuropathy taken as one group<BR/>No separate analyses for idiopathic peripheral neuropathy<BR/>Idiopathic peripheral neuropathy not well defined (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-07-06 15:18:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haanpaa-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-07-06 15:18:03 +0100" MODIFIED_BY="[Empty name]">
<P>Neuropathic pain of various origins, including non-diabetic painful peripheral polyneuropathy, (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:03 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Hewitt-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:03 +0100" MODIFIED_BY="Ruth Brassington">
<P>Neuropathic pain of various origins, including idiopathic sensory neuropathy<BR/>No separate analyses for idiopathic sensory neuropathy<BR/>Idiopathic sensory neuropathy not well defined (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:03 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Ho-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:03 +0100" MODIFIED_BY="Ruth Brassington">
<P>Neuropathic pain of various origins, including unspecified peripheral neuropathy (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:03 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Ho-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:03 +0100" MODIFIED_BY="Ruth Brassington">
<P>Idiopathic small fiber neuropathy (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:04 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Holbech-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:04 +0100" MODIFIED_BY="Ruth Brassington">
<P>Painful polyneuropathy of various origins, including idiopathic polyneuropathy<BR/>No separate analyses for idiopathic polyneuropathy<BR/>Idiopathic polyneuropathy not well defined (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:04 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Holbech-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:04 +0100" MODIFIED_BY="Ruth Brassington">
<P>Painful polyneuropathy of various origins, including idiopathic polyneuropathy<BR/>No separate analyses for idiopathic polyneuropathy<BR/>Idiopathic polyneuropathy not well defined (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:05 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Huge-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:05 +0100" MODIFIED_BY="Ruth Brassington">
<P>Neuropathic pain of various origins, including unspecified painful polyneuropathy (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:05 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Husstedt-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:05 +0100" MODIFIED_BY="Ruth Brassington">
<P>No separate analyses for idiopathic polyneuropathy<BR/>Idiopathic polyneuropathy not well defined (i.e. not defined as CIAP)<BR/>No useful outcome measures</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:06 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Jensen-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:06 +0100" MODIFIED_BY="Ruth Brassington">
<P>Neuropathic pain of various origins, including idiopathic sensory neuropathy<BR/>No separate analyses for idiopathic sensory neuropathy<BR/>Idiopathic sensory neuropathy not well defined (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:06 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Kishore_x002d_Kumar-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:06 +0100" MODIFIED_BY="Ruth Brassington">
<P>No separate analyses for idiopathic polyneuropathy<BR/>Idiopathic polyneuropathy not well defined (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:06 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Langohr-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:06 +0100" MODIFIED_BY="Ruth Brassington">
<P>Painful polyneuropathies of various origins (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:06 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Li-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:06 +0100" MODIFIED_BY="Ruth Brassington">
<P>No separate analyses for idiopathic polyneuropathy<BR/>Idiopathic polyneuropathy not well defined (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:07 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Low-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:07 +0100" MODIFIED_BY="Ruth Brassington">
<P>No separate analyses for idiopathic polyneuropathy<BR/>Idiopathic polyneuropathy not well defined (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-04-07 10:50:54 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Maier-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-04-07 10:50:54 +0100" MODIFIED_BY="Ruth Brassington">
<P>Neuropathic pain of various origins, including unspecified painful polyneuropathy (i.e. not defined as CIAP).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:07 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Meier-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:07 +0100" MODIFIED_BY="Ruth Brassington">
<P>Neuropathic pain of various or unclear origins, including unspecified neuropathy (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:07 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Morley-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:07 +0100" MODIFIED_BY="Ruth Brassington">
<P>Neuropathic pain of various origins, including idiopathic polyneuropathy<BR/>Idiopathic polyneuropathy not well defined (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:07 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-NCT00156689">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:07 +0100" MODIFIED_BY="Ruth Brassington">
<P>Idiopathic polyneuropathy not well defined (i.e. not defined as CIAP, inclusion criteria: normal conduction studies)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:08 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Nurmikko-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:08 +0100" MODIFIED_BY="Ruth Brassington">
<P>Neuropathic pain of various or unclear origins, including unspecified peripheral neuropathy (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:08 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Onofrj-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:08 +0100" MODIFIED_BY="Ruth Brassington">
<P>Cervical and lumbosacral painful syndromes of various origins</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:08 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Otto-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:08 +0100" MODIFIED_BY="Ruth Brassington">
<P>Painful diabetic and non-diabetic polyneuropathy of various unspecified origins</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:08 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Otto-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:08 +0100" MODIFIED_BY="Ruth Brassington">
<P>No separate analyses for idiopathic polyneuropathy<BR/>Idiopathic polyneuropathy not well defined (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:08 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Pedersen-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:08 +0100" MODIFIED_BY="Ruth Brassington">
<P>Chronic non-malignant pain of various origins, including 1 patient with unspecified painful polyneuropathy (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:09 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Raber-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:09 +0100" MODIFIED_BY="Ruth Brassington">
<P>No separate analyses for idiopathic polyneuropathy<BR/>Idiopathic polyneuropathy not well defined (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:09 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Rauck-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:09 +0100" MODIFIED_BY="Ruth Brassington">
<P>Pain of various types of unspecified origins, including peripheral neuropathic pain</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:09 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Rowbotham-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:09 +0100" MODIFIED_BY="Ruth Brassington">
<P>Pain from the central nervous system or peripheral nervous system, including peripheral neuropathy of unspecified origins (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:09 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Semenchuk-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:09 +0100" MODIFIED_BY="Ruth Brassington">
<P>Neuropathic pain of various origins, including peripheral neuropathy (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:09 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Serpell-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:09 +0100" MODIFIED_BY="Ruth Brassington">
<P>Peripheral neuropathic pain of various origins, including unspecified peripheral neuropathy (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sindrup-1999a">
<CHAR_REASON_FOR_EXCLUSION>
<P>No separate analyses for idiopathic polyneuropathy.<BR/>Idiopathic polyneuropathy not well defined (i.e. not defined as CIAP).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:10 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Sindrup-1999b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:10 +0100" MODIFIED_BY="Ruth Brassington">
<P>No separate analyses for idiopathic polyneuropathy<BR/>Idiopathic polyneuropathy not well defined (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sindrup-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>No separate analyses for idiopathic polyneuropathy.<BR/>Idiopathic polyneuropathy not well defined (i.e. not defined as CIAP).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sindrup-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>No separate analyses for idiopathic polyneuropathy.<BR/>Idiopathic polyneuropathy not well defined (i.e. not defined as CIAP).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:10 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Sindrup-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:10 +0100" MODIFIED_BY="Ruth Brassington">
<P>Painful polyneuropathy of various origins, including idiopathic polyneuropathy<BR/>No separate analyses for idiopathic polyneuropathy<BR/>Idiopathic polyneuropathy not well defined (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:10 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Vrethem-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:10 +0100" MODIFIED_BY="Ruth Brassington">
<P>No separate analyses for idiopathic polyneuropathy<BR/>Idiopathic polyneuropathy not well defined (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:11 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Wallace-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:11 +0100" MODIFIED_BY="Ruth Brassington">
<P>No separate analyses for idiopathic peripheral neuropathy<BR/>Idiopathic peripheral neuropathy not well defined (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:11 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Wallace-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:11 +0100" MODIFIED_BY="Ruth Brassington">
<P>Neuropathic pain of various origins, including unspecified peripheral neuropathy (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:11 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Wilsey-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:11 +0100" MODIFIED_BY="Ruth Brassington">
<P>Neuropathic pain of various origins, including idiopathic sensory neuropathy<BR/>No separate analyses for idiopathic sensory neuropathy<BR/>Idiopathic sensory neuropathy not well defined (i.e. not defined as CIAP)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-06-13 12:22:12 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Windebank-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-06-13 12:22:12 +0100" MODIFIED_BY="Ruth Brassington">
<P>Painful idiopathic distal symmetric neuropathy<BR/>Unclear if alcohol abuse, hypothyroidism, vitamin deficiency, pyridoxine (vitamin B6) intoxication, monoclonal gammopathy were sufficiently excluded<BR/>Unclear if electrophysiological criteria for CIAP were met</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>CIAP: chronic idiopathic axonal polyneuropathy.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-11-16 22:31:19 +0000" MODIFIED_BY="Alexander FJE Vrancken" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2017-06-13 12:22:12 +0100" MODIFIED_BY="Ruth Brassington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2017-06-13 12:22:12 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-NCT02260388">
<CHAR_STUDY_NAME MODIFIED="2016-07-06 15:46:58 +0100" MODIFIED_BY="[Empty name]">
<P>Patient assisted intervention for neuropathy: comparison of treatment in real life situations (PAIN-CONTRoLS)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2017-06-13 12:22:12 +0100" MODIFIED_BY="Ruth Brassington">
<P>Testing of 4 drugs for participants with cryptogenic sensory polyneuropathy</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-10 14:51:06 +0100" MODIFIED_BY="Ruth Brassington">
<P>Diagnosis of CSPN, Likert pain score greater than or equal to 4, aged 30 years or older</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-10 14:51:12 +0100" MODIFIED_BY="Ruth Brassington">
<P>Nortriyptilne 25 mg daily for 1 week at bedtime, then 50 mg daily for 1 week, ten 75 mg daily for the remainder of the study</P>
<P>Duloxetine 20 mg daily for 1 week, then 40 mg daily for 1 week, then 60 mg for the remainder of the study</P>
<P>Pregabalin 100 mg daily for 1 week, then 100 mg 2 times per day for 1 week, then 100 mg 3 times per day for the remainder of the study</P>
<P>Mexiletine 200 mg daily for 1 week, then 200 mg 2 times per day for 1 week, then 200 mg 3 times per day for the remainder of the study</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-12 12:30:11 +0100" MODIFIED_BY="Ruth Brassington">
<P>Change in patient-reported pain, percentage discontinuing treatment, change in general health and wellbeing using the Short Form 12 Health Survey questionnaire, pain interference, change in fatigue and quality of sleep (NIH Sleep Disturbance Scale)</P>
<P>Time frame: 12 weeks</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2016-07-06 15:54:43 +0100" MODIFIED_BY="[Empty name]">
<P>2014</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2017-05-12 12:30:15 +0100" MODIFIED_BY="Ruth Brassington">
<P>Maureen Walsh: email <A HREF="http://mwalsh@kumc.edu">mwalsh@kumc.edu</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-07-06 16:01:43 +0100" MODIFIED_BY="[Empty name]">
<P>Recruiting</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2017-05-12 14:42:26 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-NCT02597257">
<CHAR_STUDY_NAME MODIFIED="2017-04-03 16:37:44 +0100" MODIFIED_BY="Ruth Brassington">
<P>Efficacy and safety of lidocaine infusion treatment in management of neuropathic pain</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2017-05-10 14:51:22 +0100" MODIFIED_BY="Ruth Brassington">
<P>Randomized, double-blind, controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-12 14:42:26 +0100" MODIFIED_BY="Ruth Brassington">
<P>Post-herpetic neuralgia, diabetic polyneuropathy and peripheral polyneuropathy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-10 14:51:26 +0100" MODIFIED_BY="Ruth Brassington">
<P>Lidocaine continuous infusion 3 mg/kg or normal saline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-12 12:30:07 +0100" MODIFIED_BY="Ruth Brassington">
<P>11-point numeric rating scale (pain) after 1 week</P>
<P>At the end of the intervention and 4 weeks later:</P>
<P>Brief Pain Inventory Short Form</P>
<P>Short Form McGill Pain Questionnaire</P>
<P>Patient Global Impression of Change</P>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2016-07-06 16:01:32 +0100" MODIFIED_BY="[Empty name]">
<P>2015</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2017-05-12 12:30:21 +0100" MODIFIED_BY="Ruth Brassington">
<P>Yong Chul Kim, Seoul National University Hospital <A HREF="mailto:pain%40snu.ac.kr?subject=NCT02597257, 1720150047, Efficacy and Safety of Lidocaine Infusion Treatment in Management of Neuropathic Pain">pain@snu.ac.kr</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-07-06 16:01:36 +0100" MODIFIED_BY="[Empty name]">
<P>Recruiting</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-07-06 14:57:59 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-07-06 14:57:59 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-07-06 14:57:59 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2016-07-06 14:57:59 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2016-07-06 14:57:59 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-07-06 14:57:59 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-07-06 14:57:59 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-07-06 14:57:59 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-05-05 17:29:05 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2017-05-12 14:44:35 +0100" MODIFIED_BY="Ruth Brassington">
<APPENDIX ID="APP-01" MODIFIED="2017-04-03 15:59:07 +0100" MODIFIED_BY="Ruth Brassington" NO="1">
<TITLE MODIFIED="2017-04-03 15:59:07 +0100" MODIFIED_BY="Ruth Brassington">Cochrane Register of Studies Online/Cochrane Central Register of Controlled Trials (CENTRAL; crso.cochrane.org) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-07-08 07:51:39 +0100" MODIFIED_BY="[Empty name]">
<P>Search run on Thu Jul 7 2016</P>
<P>#1 (chronic idiopathic axonal polyneuropathy):TI,AB,KY 1</P>
<P>#2 ciap:TI,AB,KY 3</P>
<P>#3 (chronic NEAR3 (axonal polyneuropathy OR axonal neuropathy)):TI,AB,KY 2</P>
<P>#4 ((axonal OR idiopathic OR cryptogenic) NEAR (polyneuropathy OR neuropathy)):TI,AB,KY 44</P>
<P>#5 #1 OR #2 OR #3 OR #4 46</P>
<P>#6 (polyneuropathy OR "peripheral neuropathy") 2355</P>
<P>#7 "painful neuropathy" OR "painful polyneuropathy" OR "neuropathic pain" 1170</P>
<P>#8 #6 AND #7 187</P>
<P>#9 #5 OR #8 230</P>
<P>#10 (random* OR placebo* OR crossover OR cross-over) NEAR (trial OR study) 557938</P>
<P>#11 #9 AND #10 188</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2017-03-17 09:53:18 +0000" MODIFIED_BY="Ruth Brassington" NO="2">
<TITLE MODIFIED="2017-03-17 09:53:18 +0000" MODIFIED_BY="Ruth Brassington">The Cochrane Library (cochranelibrary.com) (Cochrane reviews, Cochrane Central Register of Controlled Trials) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-02-25 15:10:53 +0000" MODIFIED_BY="[Empty name]">
<P>Date Run:08/07/16 10:41:31.253<BR/>Description:<BR/>
<BR/>IDSearchHits<BR/>#1chronic idiopathic axonal polyneuropathy 10<BR/>#2ciap 8<BR/>#3chronic near/3 (axonal polyneuropathy or axonal neuropathy) 8<BR/>#4(axonal or idiopathic or cryptogenic) near (polyneuropathy or neuropathy) 77<BR/>#5#1 or #2 or #3 or #4 85<BR/>#6(polyneuropathy or "peripheral neuropathy") 2805<BR/>#7"painful neuropathy" or "painful polyneuropathy" or "neuropathic pain" 1490<BR/>#8#6 and #7 262<BR/>#9#5 or #8 334<BR/>#10(random* or placebo* or crossover or cross over) near (trial or study) 597732<BR/>#11#9 and #10 Publication Year from 1981 to 2016, in Cochrane Reviews (Reviews and Protocols), Other Reviews, Trials and Cochrane Groups, with Neuromuscular Disease Group</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2017-03-08 14:21:19 +0000" MODIFIED_BY="Ruth Brassington" NO="3">
<TITLE MODIFIED="2017-03-08 14:21:19 +0000" MODIFIED_BY="Ruth Brassington">MEDLINE (ovidsp.tx.ovid.com) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-07-08 12:19:09 +0100" MODIFIED_BY="[Empty name]">
<P>Date of search: 08-07-2016</P>
<P>Database: Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) &lt;1946 to Present&gt;</P>
<P>Search Strategy:</P>
<P>--------------------------------------------------------------------------------</P>
<P>1 randomized controlled trial.mp. (438735)</P>
<P>2 controlled clinical trial.mp. (101181)</P>
<P>3 (single-blind method or double-blind method or cross-over studies or random allocation or control groups or clinical trial or multicenter study or meta-analysis).mp. (1046661)</P>
<P>4 2 or 3 (1046661)</P>
<P>5 (trial or placebo or dummy or sham or random$).tw. (1163656)</P>
<P>6 4 and 5 (487843)</P>
<P>7 1 or 6 (655866)</P>
<P>8 (drug therapy or "therapeutic use").fs. (2537844)</P>
<P>9 7 and 8 (282078)</P>
<P>10 exp animals/ not humans.sh. (4276104)</P>
<P>11 9 not 10 (272971)</P>
<P>12 chronic idiopathic axonal polyneuropath$.tw. (49)</P>
<P>13 (ciap and axonal).tw. (32)</P>
<P>14 (chronic adj10 axonal neuropath$).tw. (84)</P>
<P>15 (chronic adj10 axonal polyneuropath$).tw. (85)</P>
<P>16 ((axonal or cryptogenic or idiopathic) adj10 neuropath$).tw. (3642)</P>
<P>17 ((axonal or cryptogenic or idiopathic) adj10 polyneuropath$).tw. (1046)</P>
<P>18 12 or 13 or 14 or 15 or 16 or 17 (4349)</P>
<P>19 exp polyneuropathies/ or polyneuropath$.tw. (31703)</P>
<P>20 peripheral neuropath$.tw. (16237)</P>
<P>21 19 or 20 (45651)</P>
<P>22 (painful or neuropathic pain).tw. (60576)</P>
<P>23 21 and 22 (2545)</P>
<P>24 (idiopathic or cryptogenic).mp. (107469)</P>
<P>25 23 and 24 (62)</P>
<P>26 18 or 25 (4363)</P>
<P>27 (11 and 22) not painful.tw. (566)</P>
<P>28 11 and 26 (26)</P>
<P>29 27 or 28 (589)</P>
<P>30 limit 29 to yr="1981-Current" (589)</P>
<P>31 remove duplicates from 30 (564)</P>
<P>***************************</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2017-03-17 09:47:57 +0000" MODIFIED_BY="Ruth Brassington" NO="4">
<TITLE MODIFIED="2017-03-17 09:47:57 +0000" MODIFIED_BY="Ruth Brassington">Embase (embase.com) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2016-07-08 11:59:24 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Embase Session Results (6 Jul 2016)</HEADING>
<TABLE COLS="3" ROWS="28">
<TR>
<TH>
<P>No.</P>
</TH>
<TH>
<P>Query</P>
</TH>
<TH>
<P>Results</P>
</TH>
</TR>
<TR>
<TH>
<P>#27</P>
</TH>
<TD>
<P>#11 AND #25 AND [1981-2016]/py</P>
</TD>
<TD>
<P>87</P>
</TD>
</TR>
<TR>
<TH>
<P>#26</P>
</TH>
<TD>
<P>#11 AND #25</P>
</TD>
<TD>
<P>87</P>
</TD>
</TR>
<TR>
<TH>
<P>#25</P>
</TH>
<TD>
<P>#20 OR #23 OR #24</P>
</TD>
<TD>
<P>6880</P>
</TD>
</TR>
<TR>
<TH>
<P>#24</P>
</TH>
<TD>
<P>#20 AND #22</P>
</TD>
<TD>
<P>321</P>
</TD>
</TR>
<TR>
<TH>
<P>#23</P>
</TH>
<TD>
<P>#18 AND #21</P>
</TD>
<TD>
<P>81</P>
</TD>
</TR>
<TR>
<TH>
<P>#22</P>
</TH>
<TD>
<P>'neuropathic pain'</P>
</TD>
<TD>
<P>29230</P>
</TD>
</TR>
<TR>
<TH>
<P>#21</P>
</TH>
<TD>
<P>painful NEXT/10 (neuropath* OR polyneuropath*)</P>
</TD>
<TD>
<P>3315</P>
</TD>
</TR>
<TR>
<TH>
<P>#20</P>
</TH>
<TD>
<P>#16 OR #19</P>
</TD>
<TD>
<P>6867</P>
</TD>
</TR>
<TR>
<TH>
<P>#19</P>
</TH>
<TD>
<P>#17 AND #18</P>
</TD>
<TD>
<P>1641</P>
</TD>
</TR>
<TR>
<TH>
<P>#18</P>
</TH>
<TD>
<P>cryptogenic OR idiopathic</P>
</TD>
<TD>
<P>154739</P>
</TD>
</TR>
<TR>
<TH>
<P>#17</P>
</TH>
<TD>
<P>polyneuropathy OR 'peripheral neuropathy' OR 'sensorimotor neuropathy' OR 'sensory neuropathy'</P>
</TD>
<TD>
<P>78908</P>
</TD>
</TR>
<TR>
<TH>
<P>#16</P>
</TH>
<TD>
<P>#12 OR #13 OR #14 OR #15</P>
</TD>
<TD>
<P>5876</P>
</TD>
</TR>
<TR>
<TH>
<P>#15</P>
</TH>
<TD>
<P>(axonal OR idiopathic OR cryptogenic) NEXT/10 (neuropath* OR polyneuropath*)</P>
</TD>
<TD>
<P>5876</P>
</TD>
</TR>
<TR>
<TH>
<P>#14</P>
</TH>
<TD>
<P>chronic NEXT/10 ('axonal neuropathy' OR 'axonal neuropathies' OR 'axonal polyneuropathy' OR 'axonal polyneuropathies')</P>
</TD>
<TD>
<P>204</P>
</TD>
</TR>
<TR>
<TH>
<P>#13</P>
</TH>
<TD>
<P>ciap AND axonal</P>
</TD>
<TD>
<P>46</P>
</TD>
</TR>
<TR>
<TH>
<P>#12</P>
</TH>
<TD>
<P>'chronic idiopathic axonal' NEXT/1 (neuropath* OR polyneuropath*)</P>
</TD>
<TD>
<P>70</P>
</TD>
</TR>
<TR>
<TH>
<P>#11</P>
</TH>
<TD>
<P>#9 NOT #10</P>
</TD>
<TD>
<P>324394</P>
</TD>
</TR>
<TR>
<TH>
<P>#10</P>
</TH>
<TD>
<P>'nonhuman'/exp NOT 'human'/exp</P>
</TD>
<TD>
<P>3742697</P>
</TD>
</TR>
<TR>
<TH>
<P>#9</P>
</TH>
<TD>
<P>#5 AND #8</P>
</TD>
<TD>
<P>326002</P>
</TD>
</TR>
<TR>
<TH>
<P>#8</P>
</TH>
<TD>
<P>#1 OR #7</P>
</TD>
<TD>
<P>711796</P>
</TD>
</TR>
<TR>
<TH>
<P>#7</P>
</TH>
<TD>
<P>#4 AND #6</P>
</TD>
<TD>
<P>501083</P>
</TD>
</TR>
<TR>
<TH>
<P>#6</P>
</TH>
<TD>
<P>#2 OR #3</P>
</TD>
<TD>
<P>659625</P>
</TD>
</TR>
<TR>
<TH>
<P>#5</P>
</TH>
<TD>
<P>'drug therapy':de,lnk,cl</P>
</TD>
<TD>
<P>3653522</P>
</TD>
</TR>
<TR>
<TH>
<P>#4</P>
</TH>
<TD>
<P>trial OR placebo OR dummy OR sham OR random*</P>
</TD>
<TD>
<P>2299323</P>
</TD>
</TR>
<TR>
<TH>
<P>#3</P>
</TH>
<TD>
<P>'crossover procedure' OR 'comparative effectiveness' OR 'factorial design' OR 'single blind procedure' OR 'double blind procedure' OR 'triple blind procedure' OR 'study design'</P>
</TD>
<TD>
<P>384332</P>
</TD>
</TR>
<TR>
<TH>
<P>#2</P>
</TH>
<TD>
<P>'controlled clinical trial'</P>
</TD>
<TD>
<P>377972</P>
</TD>
</TR>
<TR>
<TH>
<P>#1</P>
</TH>
<TD>
<P>'randomized controlled trial'</P>
</TD>
<TD>
<P>512011</P>
</TD>
</TR>
</TABLE>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2017-04-03 15:59:07 +0100" MODIFIED_BY="Ruth Brassington" NO="5">
<TITLE MODIFIED="2017-03-08 14:21:56 +0000" MODIFIED_BY="Ruth Brassington">Web of Science (apps.webofknowledge.com) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-04-03 15:59:07 +0100" MODIFIED_BY="Ruth Brassington">
<P>Date of search: 07-07-2016</P>
<P>
<B>Search History:</B>
</P>
<TABLE COLS="3" ROWS="37">
<TR>
<TD VALIGN="TOP">
<P/>
<P>
<B>Set</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
<P>
<B>Results</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 18</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>158</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>#17 AND #7</P>
<P/>
<P>
<I>Indexes=SCI-EXPANDED, SSCI, A&amp;HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</I>
</P>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 17</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=17&amp;SID=Q1a98UiiJwEe65Fc8wN&amp;search_mode=CombineSearches&amp;update_back2search_link_param=yes">2,532</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>#16 OR #12</P>
<P/>
<P>
<I>Indexes=SCI-EXPANDED, SSCI, A&amp;HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</I>
</P>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 16</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=16&amp;SID=Q1a98UiiJwEe65Fc8wN&amp;search_mode=CombineSearches&amp;update_back2search_link_param=yes">188</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>#15 AND #10</P>
<P/>
<P>
<I>Indexes=SCI-EXPANDED, SSCI, A&amp;HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</I>
</P>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 15</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=15&amp;SID=Q1a98UiiJwEe65Fc8wN&amp;search_mode=CombineSearches&amp;update_back2search_link_param=yes">6,600</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>#14 AND #13</P>
<P/>
<P>
<I>Indexes=SCI-EXPANDED, SSCI, A&amp;HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</I>
</P>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 14</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=14&amp;SID=Q1a98UiiJwEe65Fc8wN&amp;search_mode=AdvancedSearch&amp;update_back2search_link_param=yes">82,478</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>TS=(neuropathy OR polyneuropathy)</P>
<P/>
<P>
<I>Indexes=SCI-EXPANDED, SSCI, A&amp;HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</I>
</P>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 13</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=13&amp;SID=Q1a98UiiJwEe65Fc8wN&amp;search_mode=AdvancedSearch&amp;update_back2search_link_param=yes">61,090</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>TS=painful OR TS=(neuropathic pain)</P>
<P/>
<P>
<I>Indexes=SCI-EXPANDED, SSCI, A&amp;HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</I>
</P>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 12</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=12&amp;SID=Q1a98UiiJwEe65Fc8wN&amp;search_mode=CombineSearches&amp;update_back2search_link_param=yes">2,532</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>#11 OR #8</P>
<P/>
<P>
<I>Indexes=SCI-EXPANDED, SSCI, A&amp;HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</I>
</P>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 11</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=11&amp;SID=Q1a98UiiJwEe65Fc8wN&amp;search_mode=CombineSearches&amp;update_back2search_link_param=yes">2,532</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>#10 AND #9</P>
<P/>
<P>
<I>Indexes=SCI-EXPANDED, SSCI, A&amp;HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</I>
</P>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 10</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=10&amp;SID=Q1a98UiiJwEe65Fc8wN&amp;search_mode=AdvancedSearch&amp;update_back2search_link_param=yes">115,146</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>TS=(idiopathic) OR TS=(cryptogenic)</P>
<P/>
<P>
<I>Indexes=SCI-EXPANDED, SSCI, A&amp;HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</I>
</P>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 9</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=9&amp;SID=Q1a98UiiJwEe65Fc8wN&amp;search_mode=AdvancedSearch&amp;update_back2search_link_param=yes">133,612</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>TS=(neuropath*) OR TS=(polyneuropathy)</P>
<P/>
<P>
<I>Indexes=SCI-EXPANDED, SSCI, A&amp;HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</I>
</P>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 8</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=8&amp;SID=Q1a98UiiJwEe65Fc8wN&amp;search_mode=AdvancedSearch&amp;update_back2search_link_param=yes">2,532</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>TS=(idiopathic neuropath*) OR TS=(idiopathic polyneuropathy) OR TS=(cryptogenic neuropath*) OR TS=(cryptogenic polyneuropathy) OR TS=(chronic idiopathic axonal polyneuropathy)</P>
<P/>
<P>
<I>Indexes=SCI-EXPANDED, SSCI, A&amp;HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</I>
</P>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 7</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=7&amp;SID=Q1a98UiiJwEe65Fc8wN&amp;search_mode=CombineSearches&amp;update_back2search_link_param=yes">981,085</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>#6 AND #4</P>
<P/>
<P>
<I>Indexes=SCI-EXPANDED, SSCI, A&amp;HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</I>
</P>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 6</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=6&amp;SID=Q1a98UiiJwEe65Fc8wN&amp;search_mode=CombineSearches&amp;update_back2search_link_param=yes">3,254,651</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>#5 OR #1</P>
<P/>
<P>
<I>Indexes=SCI-EXPANDED, SSCI, A&amp;HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</I>
</P>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 5</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=5&amp;SID=Q1a98UiiJwEe65Fc8wN&amp;search_mode=CombineSearches&amp;update_back2search_link_param=yes">2,800,972</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>#3 AND #2</P>
<P/>
<P>
<I>Indexes=SCI-EXPANDED, SSCI, A&amp;HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</I>
</P>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 4</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=4&amp;SID=Q1a98UiiJwEe65Fc8wN&amp;search_mode=AdvancedSearch&amp;update_back2search_link_param=yes">1,378,127</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>TS=(random*)</P>
<P/>
<P>
<I>Indexes=SCI-EXPANDED, SSCI, A&amp;HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</I>
</P>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 3</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=3&amp;SID=Q1a98UiiJwEe65Fc8wN&amp;search_mode=AdvancedSearch&amp;update_back2search_link_param=yes">16,086,029</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>TS=(trial) OR TS=(study) OR TS=(treatment) OR TS=(treated) OR TS=(therap*)</P>
<P/>
<P>
<I>Indexes=SCI-EXPANDED, SSCI, A&amp;HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</I>
</P>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 2</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=2&amp;SID=Q1a98UiiJwEe65Fc8wN&amp;search_mode=AdvancedSearch&amp;update_back2search_link_param=yes">4,955,372</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>TS=(placebo) OR TS=(blind*) OR TS=(control*) OR TS=(crossover) OR TS=(cross-over)</P>
<P/>
<P>
<I>Indexes=SCI-EXPANDED, SSCI, A&amp;HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</I>
</P>
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P># 1</P>
</TD>
<TD VALIGN="TOP">
<P>
<A HREF="http://apps.webofknowledge.com/summary.do?product=WOS&amp;doc=1&amp;qid=1&amp;SID=Q1a98UiiJwEe65Fc8wN&amp;search_mode=AdvancedSearch&amp;update_back2search_link_param=yes">977,983</A>
</P>
</TD>
<TD VALIGN="TOP">
<P>TS=(random* trial) OR TS=(random* study) OR TS=(random* treatment) OR TS=(randomi* therap*)</P>
<P/>
<P>
<I>Indexes=SCI-EXPANDED, SSCI, A&amp;HCI, CPCI-S, CPCI-SSH, ESCI Timespan=All years</I>
</P>
<P/>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2017-03-08 14:22:08 +0000" MODIFIED_BY="Ruth Brassington" NO="6">
<TITLE MODIFIED="2017-03-08 14:22:08 +0000" MODIFIED_BY="Ruth Brassington">ClinicalTrials.gov search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-02-25 15:09:06 +0000" MODIFIED_BY="[Empty name]">
<P>Date of search: 07-07-2016</P>
<P>Search Terms: polyneuropathy</P>
<P>Targeted Search Conditions: polyneuropathy</P>
<P>Search syntax: polyneuropathy AND polyneuropathy [DISEASE]</P>
<P>Result: 251 studies found</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2017-05-12 14:44:35 +0100" MODIFIED_BY="Ruth Brassington" NO="7">
<TITLE MODIFIED="2017-03-17 09:54:04 +0000" MODIFIED_BY="Ruth Brassington">WHO International Clinical Trials Registry Platform (apps.who.int/trialsearch/AdvSearch.aspx) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-05-12 14:44:35 +0100" MODIFIED_BY="Ruth Brassington">
<P>Date of search: 07-07-2016</P>
<P>Polyneuropathy in the Title AND Polyneuropathy in the Condition</P>
<P>Recruitment status is: All</P>
<P>Date of registration is up until: 07/07/2016</P>
<P>Result: 175 records for 104 trials found</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>